piperacillin has been researched along with meropenem in 343 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (3.21) | 18.2507 |
| 2000's | 116 (33.82) | 29.6817 |
| 2010's | 157 (45.77) | 24.3611 |
| 2020's | 59 (17.20) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Alba, L; Chen, Y; Garber, E; Saiman, L; Tabibi, S; Zhou, J | 1 |
| Dumas, JL; Köhler, T; Reinhardt, A; Ricou, B; Rohner, P; van Delden, C; Wood, P | 1 |
| Correa, A; Kattan, JN; Lolans, K; Lopez, JA; Quinn, JP; Villegas, MV | 1 |
| Caniça, M; Ferreira, E; Leitão, J; Manageiro, V; Mendonça, N | 1 |
| Bonomo, RA; Endimiani, A; Hujer, AM; Hujer, KM; Luzzaro, F; Mantengoli, E; Migliavacca, R; Pagani, L; Rossolini, GM; Toniolo, A | 1 |
| Ariza, J; Dominguez, MA; Gudiol, F; Guzmán, A; Peña, C; Pujol, M; Suarez, C; Tubau, F | 1 |
| Cattoir, V; Corvec, S; Drugeon, H; Faccone, D; Galas, M; Mugnier, P; Nordmann, P; Pasteran, F; Petroni, A; Poirel, L; Rapoport, M | 1 |
| Adams, J; Paterson, DL; Peleg, AY | 1 |
| Kamat, V; Sekar, U; Toleman, MA; Vinodh, H; Walsh, TR | 1 |
| Avlami, A; Daikos, GL; Katsilambros, N; Kosmidis, C; Petrikkos, G; Psychogiou, M; Stefanou, I; Tassios, PT; Vasilakopoulou, A | 1 |
| Amicosante, G; Caporale, B; Celenza, G; Docquier, JD; Mezzatesta, M; Pellegrini, C; Perilli, M; Rossolini, GM; Stefani, S | 1 |
| Castanheira, M; Jones, RN; Mendes, RE; Sader, HS; Toleman, MA; Walsh, TR | 1 |
| Carmeli, Y; Chmelnitsky, I; Leavitt, A; Navon-Venezia, S; Schwaber, MJ | 1 |
| Grosso, F; Peixe, L; Quinteira, S; Ramos, H | 1 |
| Beceiro, A; Bou, G; Canle, D; Fernández, A; Lasa, I; Latasa, C; Mallo, S; Molina, F; Pérez, A; Pérez, S; Poza, M; Tomás, Mdel M; Villanueva, R | 1 |
| Henrichfreise, B; Luhmer-Becker, I; Wiedemann, B; Wiegand, I | 1 |
| Fung, CP; Hsieh, YP; Hu, WS; Lin, JF; Liu, CP; Yao, SM | 1 |
| Correia, A; Domingues, MR; Domingues, P; Fonseca, F; Henriques, I; Saavedra, MJ; Samyn, B; Sarmento, AC; van Beeumen, J | 1 |
| Bonnet, R; Neuwirth, C; Robin, F; Siebor, E | 1 |
| Bouza, E; Cercenado, E; Coll, P; Gutiérrez, O; Juan, C; Navarro, F; Oliver, A; Pérez, JL | 1 |
| Cuzon, G; Demachy, MC; Naas, T; Nordmann, P | 1 |
| Hsiao, YJ; Hu, RM; Huang, KJ; Wu, LT; Yang, TC | 1 |
| Avison, MB; Okazaki, A | 1 |
| Courvalin, P; Dupêchez, M; Galimand, M; Lambert, T; Meziane-Cherif, D | 1 |
| Cuzon, G; Lartigue, MF; Naas, T; Nordmann, P; Quinn, JP; Villegas, MV | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Mataseje, L; Mulvey, MR; Nichol, K; Zhanel, GG | 1 |
| Cai, JC; Chen, GX; Zhang, R; Zhou, HW | 1 |
| Castanheira, M; Deshpande, LM; Martin, CA; Morita, K; Ribes, JA; Sader, HS | 1 |
| Bethel, CR; Bonomo, RA; Carias, LL; Endimiani, A; Fox, WR; Hall, GS; Hujer, AM; Hujer, KM; Hutton, RA; Jacobs, MR; Jenkins, SG; Paterson, DL; Perez, F; Rice, LB; Tenover, FC | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Docquier, JD; Frère, JM; Rossolini, GM; Stoczko, M | 1 |
| Carrillo, B; Esparza-Ahumada, S; Garza-Ramos, U; Hernández, E; Jones, RN; Morfin-Otero, R; Rodriguez-Noriega, E; Sader, HS; Sanchez, A; Silva-Sanchez, J | 1 |
| Alba, V; Blasco, MD; Espinal, P; Fernández-Cuenca, F; Marti, S; Pascual, A; Ruiz, M; Sánchez-Céspedes, J; Vila, J | 1 |
| Badur, S; Cagatay, AA; Carrër, A; Eraksoy, H; Nordmann, P; Poirel, L | 1 |
| Carmeli, Y; Chmelnitsky, I; Navon-Venezia, S; Strahilevitz, J | 1 |
| Bauernfeind, A; Keuleyan, E; Markovska, R; Queenan, AM; Rasshofer, R; Schneider, I | 1 |
| Castanheira, M; Samuelsen, Ø; Spencer, J; Walsh, TR | 1 |
| Hsueh, PR; Huang, YT; Liao, CH; Lin, HY; Liu, CY; Yen, LC | 1 |
| Albertí, S; Beceiro, A; Bou, G; Garau, M; Gutiérrez, O; Juan, C; Oliver, A; Pérez, JL | 1 |
| Bogaerts, P; Cuzon, G; Glupczynski, Y; Huang, TD; Naas, T; Nordmann, P | 1 |
| Fujimoto, S; Ike, Y; Okuzumi, K; Tanimoto, K; Tomita, H | 1 |
| Karlowsky, JA; Laing, NM; Zhanel, GG | 1 |
| Afif, C; Bagattini, M; Daoud, Z; Di Popolo, A; Khan, AU; Triassi, M; Vitale, D; Zarrilli, R | 1 |
| Kanamori, M; Kirikae, T; Kitao, T; Miyoshi-Akiyama, T; Morita, K; Okazaki, M; Sekiguchi, J; Watanabe, N | 1 |
| Brown, NP; Pillar, CM; Sahm, DF; Shah, D; Torres, MK | 1 |
| Chen, H; Chen, M; Wang, H; Yang, H; Yang, Q | 1 |
| Amicosante, G; De Luca, F; Luzzaro, F; Migliavacca, R; Mugnaioli, C; Pagani, L; Perilli, M; Pini, B; Pollini, S; Rossolini, GM; Spalla, M; Toniolo, A | 1 |
| Jacobus, NV; McDermott, LA; Snydman, DR | 1 |
| Bennett, JW; Herrera, ML; Jorgensen, JH; Lewis, JS; Wickes, BW | 1 |
| Arakawa, Y; Ishikawa, K; Nagano, N; Nagano, Y; Wachino, J | 1 |
| Baptista, BC; Correia, JD; da Fonseca, JD; Martínez-Martínez, L; Pomba, C | 1 |
| Bell, JM; Castanheira, M; Deshpande, LM; Jones, RN; Mendes, RE; Turnidge, JD | 1 |
| Asensi, MD; Gales, AC; Monteiro, J; Peirano, G; Santos, AF | 1 |
| Goering, RV; Hanson, ND; Kurpiel, PM; Palepou, MF; Wolter, DJ; Woodford, N | 1 |
| Beceiro, A; Bou, G; Cisneros, JM; Fernández-Cuenca, F; Martínez-Martínez, L; Pachón, J; Pascual, A; Pérez, A; Rodríguez-Baño, J; Vila, J | 1 |
| Nordmann, P; Plésiat, P; Poirel, L; Rodriguez-Martinez, JM | 1 |
| Bell, JM; Castanheira, M; Jones, RN; Mathai, D; Turnidge, JD | 1 |
| Baraniak, A; Bedenic, B; Fiett, J; Gniadkowski, M; Jajic-Bencic, I; Literacka, E; Tonkic, M | 1 |
| Aquino, EE; Goering, RV; Hanson, ND; Khalaf, N; Robledo, IE; Santé, MI; Vázquez, GJ; Wolter, DJ | 1 |
| Duljasz, W; Gniadkowski, M; Jebelean, C; Sitter, S; Wojna, A | 1 |
| Nordmann, P; Poirel, L; Rodríguez-Martínez, JM | 1 |
| Kirikae, T; Kitao, T; Miyoshi-Akiyama, T | 1 |
| Hall, RM; Post, V | 1 |
| Hu, RM; Huang, SC; Huang, YW; Lin, YT; Yang, TC | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hafkin, B; Hoban, DJ; Kaplan, N; Karlowsky, JA; Zhanel, GG | 1 |
| Ghori, S; Griggs, DJ; Johnson, MM; Mott, A; Peake, L; Piddock, LJ | 1 |
| Giakkoupi, P; Miriagou, V; Papagiannitsis, CC; Pappa, O; Polemis, M; Tzouvelekis, LS; Vatopoulos, AC; Zioga, A | 1 |
| Gales, AC; Nordmann, P; Picão, RC; Poirel, L | 1 |
| Baraniak, A; Fiett, J; Filczak, K; Gniadkowski, M; Herda, M; Hryniewicz, W; Izdebski, R; Kern-Zdanowicz, I; Łopaciuk, U | 1 |
| Bauernfeind, A; Keuleyan, E; Markova, B; Markovska, R; Queenan, AM; Schneider, I | 1 |
| Du, X; Ji, S; Jiang, Y; Li, L; Shen, P; Wei, Z; Yu, Y | 1 |
| Hancock, RE; Kiffer, CR; Mendes, CM; Sampaio, JL; Schurek, KN; Sinto, S | 1 |
| Arai, K; Hasegawa, M; Hatta, M; Hirakata, Y; Jones, RN; Kaku, M; Kawakami, K; Kitagawa, M; Kobayashi, I; Kohno, S; Kunishima, H; Matsuzaki, K; Mikuriya, M; Ohmori, K; Saika, T; Yamaguchi, K; Yamamoto, N; Yano, H | 1 |
| De Luca, F; Delmarcelle, M; Docquier, JD; Dubus, A; Frère, JM; Nacoulma, OG; Rossolini, GM; Simporé, J; Zeba, B | 1 |
| Carattoli, A; Ellington, MJ; Karisik, E; Livermore, DM; Underwood, A; Woodford, N | 1 |
| Acosta, J; Chaves, F; Juan, C; Oliver, A; Otero, JR; Sanz, F; Viedma, E; Zamorano, L | 1 |
| Cho, HS; Giske, CG; Lee, K; Sundman, K; Toleman, MA; Walsh, TR; Yong, D | 1 |
| Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Higgins, PG; Lehmann, M; Nordmann, P; Poirel, L; Seifert, H | 1 |
| Bulik, CC; Crandon, JL; Nicolau, DP | 1 |
| Ichiishi, S; Mikamo, H; Nakao, K; Shibata, T; Tanaka, K; Watanabe, K | 1 |
| Girlich, D; Nordmann, P; Poirel, L | 3 |
| Aggoune-Khinache, N; Bonnet, R; Delmas, J; Naim, M; Robin, F | 1 |
| Fortineau, N; Nordmann, P; Poirel, L; Rodriguez-Martinez, JM | 1 |
| Ge, Y; Juan, C; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Akan, OA; Carrër, A; Cuzon, G; Feriha, C; Honderlick, P; Matar, G; Nordmann, P; Poirel, L; Yilmaz, M | 1 |
| Ge, Y; Juan, C; Moya, B; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Chang, SC; Chen, YC; Hsia, KC; Li, SY; Liao, MH; Lin, YC; Sheng, WH | 1 |
| Choi, JY; Ko, KS; Lee, MY; Park, YK; Peck, KR; Rhee, JY; Shin, JY; Song, JH | 1 |
| Carmeli, Y; Chmelnitsky, I; Goren, MG; Navon-Venezia, S | 1 |
| Al Naiemi, N; Debets-Ossenkopp, YJ; Nordmann, P; Poirel, L; Rodríguez-Martínez, JM | 1 |
| Carmeli, Y; Chmelnitsky, I; Goren, MG; Leavitt, A; Navon-Venezia, S; Ofek, I | 1 |
| Chang, FY; Chen, TL; Fung, CP; Huang, LY; Lu, PL; Siu, LK | 1 |
| Chung, TC; Hu, RM; Huang, YW; Lin, CW; Lin, YT; Yang, TC | 1 |
| Barber, M; Eberly, LE; Feeney, LA; Miller, GH; Summers, A; Wortmann, G; Zapor, MJ | 1 |
| Bonomo, RA; Distler, AM; Endimiani, A; Hornick, JM; Hujer, AM; Hujer, KM; Papp-Wallace, KM; Taracila, M | 1 |
| Abele-Horn, M; Claus, H; Elias, J; Engelhardt, K; Frosch, M; Joseph, B; Oesterlein, A; Schoen, C; Turnwald, D; Valenza, G | 1 |
| Bini, L; Bonomo, RA; Borgianni, L; Docquier, JD; Frère, JM; Matagne, A; Rossolini, GM; Vandenameele, J | 1 |
| Chang, WC; Chen, CP; Chen, TL; Cho, WL; Fung, CP; Kuo, SC; Lee, YT; Siu, LK | 1 |
| Cars, O; Löwdin, E; Melhus, A; Tängdén, T | 1 |
| Jiang, Y; Shen, P; Wei, Z; Yu, D; Yu, Y; Zhou, Z | 1 |
| Nordmann, P; Poirel, L; Rodríguez-Martínez, JM; Ronco, E | 1 |
| Cabot, G; Deng, L; Juan, C; Mark, BL; Moyá, B; Oliver, A; Reeve, TM; Vocadlo, DJ; Zamorano, L | 1 |
| Chong, Y; Jeong, SH; Kim, MS; Lee, K; Lee, Y; Park, Y; Yong, D | 1 |
| Bai, N; Cai, Y; Li, R; Liang, B; Liu, Y; Wang, R | 1 |
| Carattoli, A; García-Fernández, A; Giordano, A; Mancini, C; Miriagou, V; Papagiannitsis, CC; Venditti, M | 1 |
| Kotsakis, SD; Miriagou, V; Tzelepi, E; Tzouvelekis, LS | 1 |
| Benvenuti, M; Calderone, V; Docquier, JD; Mangani, S; Menciassi, N; Rossolini, GM; Stoczko, M | 1 |
| Chang, FY; Chen, TL; Fung, CP; Hsueh, PR; Ko, WC; Kuo, SC; Lee, YT; Siu, LK | 1 |
| Lagrutta, E; Nordmann, P; Pham, J; Poirel, L; Taylor, P | 1 |
| Chien, CC; Lee, CH; Li, CC; Liu, JW; Su, LH; Tang, YF | 1 |
| Bae, IK; Jeong, SH; Kim, J; Lee, K; Suh, B; Yong, D | 1 |
| Hamprecht, A; Higgins, PG; Schneiders, T; Seifert, H | 1 |
| Bonomo, RA; Endimiani, A; Hujer, AM; Hujer, KM; Pulse, ME; Weiss, WJ | 1 |
| Borgianni, L; Docquier, JD; Hanson, ND; Prandi, S; Rossolini, GM; Salden, L; Santella, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bojkovic, J; Dean, CR; Dobler, M; Dzink-Fox, J; Glick, M; Hamann, LG; Kerrigan, J; Lanieri, L; Lenoir, F; Lilly, MD; Liu, E; Lu, Y; McKenney, D; Nunez, J; Osborne, C; Parker, DT; Patnaik, A; Peng, Y; Piizzi, G; Ranjitkar, S; Sprague, ER; Tommasi, R; Wang, B; Wang, H; Wattanasin, S; Xie, L; Yang, X; Yu, D | 1 |
| Bermingham, A; Blais, J; Capka, V; Cariaga, T; Casarez, A; Colvin, R; Dean, CR; Fekete, A; Gong, W; Growcott, E; Guo, H; Jones, AK; Li, C; Li, F; Lin, X; Lindvall, M; Lopez, S; McKenney, D; Metzger, L; Moser, HE; Prathapam, R; Rasper, D; Reck, F; Rudewicz, P; Sethuraman, V; Shaul, J; Shen, X; Simmons, RL; Tang, D; Tashiro, K; Tjandra, M; Turner, N; Uehara, T; Vitt, C; Whitebread, S; Yifru, A; Zang, X; Zhu, Q | 1 |
| Björkling, F; Bonke, G; Franzyk, H; Hansen, AM; Hogendorf, WFJ; Kongstad, KT; Nielsen, J; Nielsen, PE; Tomczak, M; Urbas, M; Zabicka, D | 1 |
| Brunst, S; Burgers, LD; Frank, D; Fürst, R; Gobec, S; Martinelli, G; Proschak, A; Proschak, E; Rotter, MJ; Sosič, I; Weizel, L; Wichelhaus, TA | 1 |
| Cherubin, CE; Citron, DM; Goldstein, EJ; Hillier, SL | 1 |
| Mandell, GL; Townsend, GC | 1 |
| Iaconis, JP; Nadler, HL; Pitkin, DH; Sheikh, W | 1 |
| Falagas, ME; McDermott, L; Snydman, DR | 1 |
| Chen, HY; Livermore, DM | 1 |
| Awaya, Y; Fujiue, Y; Kodomari, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y | 1 |
| Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
| Rokosz, A; Sawicka-Grzelak, A | 1 |
| Bingen, E; Bonacorsi, S; Fitoussi, F; Lhopital, S | 1 |
| Kamiya, A; Mizuno, H; Oie, S; Sawa, A | 1 |
| Fujimura, S; Gomi, K; Honda, Y; Kikuchi, T; Kobayashi, T; Nukiwa, T; Shoji, S; Takahashi, H; Tokue, Y; Watanabe, A; Yasui, S | 1 |
| Barchiesi, F; Cirioni, O; Del Prete, MS; Drenaggi, D; Fortuna, M; Giacometti, A; Scalise, G | 1 |
| Jones, RN; Mutnick, AH; Turner, PJ | 1 |
| Cao, W; Tong, MH; Wang, JG | 1 |
| Dawis, MA; France, KA; Isenberg, HD; Jenkins, SG | 1 |
| Ghuloom, A; Mysore, V | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP; Nightingale, CH | 1 |
| Ceran, N; Erdem, I; Kucukercan, M | 1 |
| Burgess, DS; Hall, RG | 1 |
| Aksoylar, S; Cetingül, N; Kansoy, S; Kantar, M; Karapinar, D; Kavakli, K | 1 |
| Abe, M; Araki, M; Horimi, T; Nasu, Y; Ono, N; Takahashi, I | 1 |
| Baysallar, M; Doğanci, L; Kiliç, A; Küçükkaraaslan, A; Senses, Z | 1 |
| Jakoniuk, P; Leszczyńska, K; Sacha, PT; Wieczorek, P; Zalewska, M | 1 |
| Bellaire, T; Cornely, OA; Dörken, B; Einsele, H; Krause, S; Kubin, T; Maschmeyer, G; Reich, G; Sandherr, M; Thiel, E | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP | 1 |
| Kuti, JL; Nicolau, DP; Sun, HK | 1 |
| Kuti, JL; Nicolau, DP; Ong, CT | 1 |
| Aydogdu, I; Ersoy, Y; Kaya, E; Kuku, I; Serefhanoglu, K; Serefhanoglu, S | 1 |
| Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
| Greenberg, A; Muallem-Zilcha, E; Raveh, D; Schlesinger, Y; Wiener-Well, Y; Yinnon, AM | 1 |
| Adam, HJ; Laing, N; Mayer, M; Zhanel, GG | 1 |
| Doi, M; Fujiue, Y; Kuwabara, M; Muroki, K; Shimizu, S; Watanabe, Y; Yano, S | 1 |
| Bardenstein, R; Carmeli, Y; Chmelnitsky, I; Goland, S; Hammer Muntz, O; Navon Venezia, S; Zimhony, O | 1 |
| Agarwal, N; Agarwal, S; Arya, SC | 1 |
| Broide, E; Raveh, D; Rudensky, B; Yinnon, AM | 1 |
| Agarwal, N; Agarwal, S; Arya, SC; Solanki, BS | 1 |
| Afonso, MR; Albertoni, Ade C; Arkader, R; Cabral, EA; da Silva, DC; de Araujo, OR; Diegues, AR; Louzada, ME | 1 |
| Akova, M; Altun, B; Gürkan Aydin, N; Hasçelik, G; Metan, G; Zarakolu, P | 1 |
| Charlier, C; Denooz, R | 1 |
| Adukauskiene, D; Dambrauskiene, A; Jeroch, J; Vitkauskiene, A | 1 |
| Nakwa, F; Velaphi, S; Wadula, J | 1 |
| Kitazato, M; Mitsuyama, J; Mizunaga, S; Morikawa, Y; Morita, T | 1 |
| Bahram, F; Emaneini, M; Fatolahzadeh, B; Feizabadi, MM; Mehdi, FM; Mohammad, E; Morovat, T; Setareh, S; Soroush, S; Taherikalani, M | 1 |
| Arias, MJ; de la Torre, A; Díaz, JA; Hernández, AP; Silva, E | 1 |
| Cavallo, JD; Chomarat, M; Dubreuil, L; Joly-Guillou, ML; Kempf, M; Maugein, J; Muller-Serieys, C; Roussel-Delvallez, M | 1 |
| De Backer, D; Delattre, I; Dugernier, T; Jacobs, F; Laterre, PF; Layeux, B; Spapen, H; Taccone, FS; Vincent, JL; Wallemacq, P; Wittebole, X | 1 |
| Buyle, F; Claus, B; Robays, H; Vogelaers, D | 1 |
| Bivas, A; Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
| Clarke, MJ; Edwards, SJ; Wordsworth, S | 1 |
| Cabot, G; Juan, C; Mark, BL; Moyá, B; Oliver, A; Reeve, TM; Vocadlo, DJ; Zamorano, L | 1 |
| Fanning, KJ; Prins, JB; Roberts, MS; Robertson, TA | 1 |
| Altunsoy, A; Aypak, C; Azap, A; Balık, I; Ergönül, Ö | 1 |
| Cotton, F; De Backer, D; Jacobs, F; Macours, P; Seyler, L; Taccone, FS; Vincent, JL | 1 |
| Gonçalves-Pereira, J; Póvoa, P | 1 |
| Cho, B; Im, SA; Park, GS; Yun, DY | 1 |
| Kronenberg, A; Mühlemann, K; Pannatier, A; Plüss-Suard, C; Ruffieux, C; Zanetti, G | 1 |
| Homann, C; Knudsen, JD; Moser, C; Novovic, S; Olsen, H; Semb, S | 1 |
| Holodniy, M; Lucero, CA; Mercier, RC; Nguyen, N; Oda, G; Ryono, RA; Schirmer, PL | 1 |
| Delattre, IK; Jacobs, F; Jacqmin, P; Laterre, PF; Musuamba, FT; Taccone, FS; Verbeeck, RK; Wallemacq, P | 1 |
| Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS | 1 |
| Lam, JP; Liu, TJ | 1 |
| Farbman, L; Gafter-Gvili, A; Leibovici, L; Paul, M; Peck, A; Raanani, P; Ram, R; Shpilberg, O; Vidal, L; Yeshurun, M | 1 |
| Beumier, M; Cotton, F; De Backer, D; Hites, M; Jacobs, F; Lorent, S; Roisin, S; Seyler, L; Surin, R; Taccone, FS; Vincent, JL; Wolff, F | 1 |
| Blake, P; Brichacek, M; Kao, R | 1 |
| Arnold, HM; Hampton, NB; Hoban, A; Hoffmann, J; Hollands, JM; Juang, PH; Kollef, MH; McCormick, S; Micek, ST; Reichley, RM; Skrupky, LP; Smith, JR | 1 |
| Imamura, Y; Izumikawa, K; Kakeya, H; Kohno, S; Kurihara, S; Miyazaki, T; Morinaga, Y; Nakamura, S; Tsukamoto, M; Yamamoto, Y; Yanagihara, K; Yasuoka, A | 1 |
| Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Miyamoto, T; Shimoda, S; Shimono, N; Yakushiji, H | 1 |
| Flamm, RK; Jones, RN; Sader, HS; Watters, AA | 1 |
| Adnan, S; Jarrett, P; Li, JX; Lipman, J; Paterson, DL; Roberts, JA; Rudd, M; Udy, AA; Wallis, SC | 1 |
| Carlier, M; Carrette, S; De Waele, JJ; Decruyenaere, J; Depuydt, P; Hoste, E; Lipman, J; Roberts, JA; Stove, V; Verstraete, A; Wallis, SC | 1 |
| El-Ghaiesh, S; Farrell, J; Hamlett, J; Jenkins, RE; Meng, X; Monshi, MM; Naisbitt, DJ; Park, BK; Peckham, D; Pirmohamed, M; Sanderson, JP; Whitaker, P; Yaseen, FS | 1 |
| Kollef, MH | 1 |
| Browning, R; Darwiche, K; Freitag, L; Kioumis, I; Li, Q; Parrish, S; Petridis, D; Porpodis, K; Ritzoulis, C; Spyratos, D; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Bandettini, R; Buffa, P; Castagnola, E; Caviglia, I; Ciucci, A; Ginocchio, F; Guida, E; Haupt, R; Loy, A; Masa, DL; Mattioli, G; Perotti, M; Pini Prato, A | 1 |
| Arakawa, S; Fujisawa, M; Miyake, H; Shigemura, K; Tanaka, K | 1 |
| Boelens, J; Carlier, M; Carrette, S; Claeys, G; De Waele, JJ; Decruyenaere, J; Depuydt, P; Hoste, E; Leroux-Roels, I; Stove, V; Verstraete, AG | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Jamal, JA; Lipman, J; Roberts, JA; Udy, AA | 1 |
| Carlier, M; De Waele, J; Decruyenaere, J; Depuydt, P; Hoste, E; Lipman, J; Roberts, JA; Wallis, SC | 1 |
| Harada, Y; Hasegawa, H; Izumikawa, K; Kaku, N; Kohno, S; Morinaga, Y; Nakamura, S; Uno, N; Yanagihara, K | 1 |
| Acipayam, C; Bayram, I; Ozkan, A; Sezgin, G; Tanyeli, A | 1 |
| Wu, H; Xie, W; Ye, Z; Zhang, W; Zhao, C | 1 |
| Calvo, G; Llauradó-Serra, M; Martín-Loeches, I; Pontes, C; Soy, D; Ulldemolins, M; Vaquer, S | 1 |
| Bandettini, R; Barco, S; Cangemi, G; Castagnola, E; Maffia, A; Tripodi, G | 1 |
| Han, X; Hu, D; Li, Q; Qu, Y; Shen, L | 1 |
| Frey, L; Maier, B; Suhr, A; Teupser, D; Vogeser, M; Zander, J; Zoller, M | 1 |
| Andersen, MH; Arendrup, MC; Bestle, MH; Cozzi-Lepri, A; Drenck, NE; Grarup, J; Hein, L; Helweg-Larsen, J; Jensen, JU; Johansen, ME; Larsen, KM; Lauritsen, AØ; Lundgren, B; Lundgren, JD; Løken, J; Mohr, T; Møller, JK; Olesen, B; Petersen, JA; Reinholdt, K; Strange, D; Søe-Jensen, P; Thormar, K; Tousi, H; Østergaard, C | 1 |
| Antonucci, E; Beumier, M; Cristallini, S; de Backer, D; Donadello, K; Jacobs, F; Roberts, JA; Rondelet, B; Scolletta, S; Taccone, FS; Vincent, JL | 1 |
| Chong, Y; Jeong, SH; Kim, M; Kim, WH; Lee, K; Lee, Y; Seo, YH; Yim, J; Yong, D | 1 |
| Lai, J; Li, S; Liang, L; Peng, B; Wang, Z; Zheng, J | 1 |
| Athan, E; Baker, P; Harris, PN; Harris-Brown, T; Ingram, PR; Iredell, J; Lipman, J; McBryde, ES; Miyakis, S; Paterson, DL; Paul, SK; Peleg, AY; Roberts, JA; Rogers, BA; Stewardson, AJ | 1 |
| Pineda, LC; Watt, KM | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Jones, RN; Mendes, RE; Sader, HS | 1 |
| Ballard, A; Biddy, BA; Bouley, R; Burnham, CA; Chang, M; Dantas, G; Gonzales, PR; Mobashery, S; Pesesky, MW; Schroeder, VA; Suckow, MA; Wolter, WR | 1 |
| Abdul-Aziz, MH; Akova, M; Bassetti, M; De Waele, JJ; Dimopoulos, G; Dulhunty, J; Kaukonen, KM; Koulenti, D; Lipman, J; Martin, C; Montravers, P; Rello, J; Rhodes, A; Roberts, JA; Starr, T; Wallis, SC | 1 |
| Livermore, DM; Mushtaq, S; Warner, M; Woodford, N | 1 |
| Gholipourmalekabadi, M; Hashemi, A; Mozafari, M; Rostami, A; Sameni, M; Zamani, F | 1 |
| Cotton, F; Creteur, J; Gustot, T; Hites, M; Jacobs, F; Lheureux, O; Surin, R; Taccone, FS; Trepo, E; Vincent, JL; Wolff, F | 1 |
| Hung, YP; Ko, WC; Lee, JC; Li, CW; Li, MC; Lin, HJ; Liu, HC; Wu, YH | 1 |
| Abdul-Aziz, MH; Alobaid, AS; Brinkmann, A; Frey, OR; Grau, S; Lipman, J; Luque, S; Roberts, JA; Roberts, MS; Roehr, AC; Wong, G | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Huband, MD; Jones, RN; Sader, HS | 1 |
| Grushnikov, A; Iino, R; Kikuchi, K; Matsumoto, Y; Nishino, K; Noji, H; Sakakihara, S; Yagi, Y; Yamaguchi, A | 1 |
| Cohen, H; Peyko, V; Smalley, S | 1 |
| Abe, T; Furuuchi, T; Ida, T; Inamura, S; Morinaka, A; Sakakibara, S; Sakamaki, Y; Takata, T; Takayama, Y; Tsujii, N; Tsutsumi, Y; Yamada, K | 1 |
| Boelens, J; Catteeuw, J; Claeys, G; De Bus, L; De Waele, JJ; Decruyenaere, J; Denys, W; Depuydt, PO; Gadeyne, B; Vermeulen, K | 1 |
| Cotta, MO; Lipman, J; Little, PJ; McDonald, C; McWhinney, B; Roberts, JA; Ungerer, JP | 1 |
| Caméléna, F; Hadj, A; Le Monnier, A; Mizrahi, A; Mollo, B; Pilmis, B | 1 |
| Chen, TL; Chuang, MF; Huang, WC; Kuo, SC; Lauderdale, TL; Lee, Y; Tseng, KC; Yang, YS | 1 |
| Brul, S; Feng, Y; Jonker, MJ; Moustakas, I; Ter Kuile, BH | 1 |
| Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
| Ji, JS; Quan, JJ; Wang, HP; Wang, Y; Wang, YF; Xu, YC; Yu, YS | 1 |
| Chen, J; Kong, C; Zhang, Y; Zhu, L; Zou, X | 1 |
| Eliasson, E; Giske, CG; Petersson, J | 1 |
| Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D | 2 |
| Casabar, E; Durkin, MJ; Hays, AJ; Hsueh, K; Jafarzadeh, SR; Krekel, T; Lane, MA; Reyes, M; Ritchie, DJ | 1 |
| Beaudoin, ME; Cavalcanti, NC; Derendorf, H; Grunwitz, C; Kircher, P; Nichols, WW; Pieper, S; Schuck, VJ; Sy, SK; Tabosa, MA; Zhuang, L | 1 |
| Compain, F; Grohs, P; Kaibi, I; Lavollay, M; Mainardi, JL; Morand, P; Podglajen, I; Taieb, G | 1 |
| Jensen, BH; Justesen, US; Krogfelt, KA; Petersen, AM; Sydenham, TV | 1 |
| Brenner, T; Hoppe-Tichy, T; Pinder, N; Swoboda, S; Weigand, MA | 1 |
| Gemperli, R; Gomez, DS; Levin, AS; Machado, AS; Oliveira, MS; Sanches, C; Santos, SRCJ; Silva Junior, CVD | 1 |
| Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
| Cohen-Wolkowiez, M; Greenberg, RG; Rivera-Chaparro, ND | 1 |
| Burgess, DR; Burgess, DS; Cotner, SE; Martin, CA; Rutter, WC; Wallace, KL | 1 |
| Mueller, BA; Shaw, AR | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Heather, CS; Maley, M | 1 |
| Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
| Kollef, MH; Micek, ST; Vazquez Guillamet, MC; Vazquez, R | 1 |
| Carlier, M; De Baets, F; Forier, K; Haerynck, F; Schelstraete, P; Stove, V; Van Braeckel, E; Van Daele, S; Van Heck, V; Van Simaey, L; Vaneechoutte, M; Verstraete, AG | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
| Buscher, H; Gentili, S; Imani, S; Marriott, D; Sandaradura, I | 1 |
| Athanasopoulos, A; Borrey, D; Carlier, M; Colin, P; Cotton, F; Denooz, R; Ghys, T; Neels, H; Spriet, I; Stove, V; Verstraete, AG | 1 |
| Choi, JK; Joo, EJ; Ko, JH; Lee, NR; Moon, SY; Park, DA; Peck, KR | 1 |
| Hatti, M; Odenholt, I; Resman, F; Solomonidi, N; Tham, J | 1 |
| Bergen, PJ; Bulitta, JB; Kirkpatrick, CMJ; Landersdorfer, CB; Lipman, J; McGregor, MJ; Millen, N; Paterson, DL; Roberts, JA; Sime, FB | 1 |
| Alexander, EL; Bhowmick, T; Bidair, M; Bleasdale, SC; Chorvat, E; Dragoescu, PO; Dudley, MN; Fedosiuk, E; Fusaro, K; Giamarellos-Bourboulis, EJ; Griffith, D; Horcajada, JP; Kaye, KS; Lomovskaya, O; Loutit, J; Metallidis, S; Morgan, E; Murta, C; Sagan, OS; Sarychev, Y; Stoev, V; Stus, V; Vazquez, J; Zaitsev, V | 1 |
| Arıcı, M; Balcı, C; Hayran, SA; Ünal, S; Uzun, Ö; Yüce, D | 1 |
| Castanheira, M; Duncan, LR; Flamm, RK; Sader, HS | 1 |
| Hao, D; Hu, Z; Liu, X; Sun, T; Tian, H; Wang, T; Wang, X | 1 |
| An, G; Bach, T; D'Cunha, R; Li, P; Nalbant, D; Winokur, P; Young, BA; Zhang, J | 2 |
| Farkas, A; Heil, EL; Nicolau, DP; Roberts, JA; Thom, KA | 1 |
| Keller, F | 1 |
| An, G; Creech, B; Fissell, WH; Groszek, JJ; Marsh, E; Patel, P; Shotwell, M; Verhoven, SM | 1 |
| Ally, M; Briscoe, S; Lipman, J; McWhinney, B; Roberts, JA; Ungerer, J; Wong, G | 1 |
| Al Khamis, M; Alenazi, TH; Arabi, Y; Athan, E; Baker, P; Bassetti, M; Beatson, SA; Bhally, H; Boyles, TH; Crowe, A; Daneman, N; Falcone, M; Griffin, P; Harris, PNA; Harris-Brown, T; Ingram, P; Iredell, J; Kanj, S; Lee, TH; Looke, D; Lorenc, P; Lye, DC; Mendelson, M; Miyakis, S; Mo, Y; Paterson, DL; Peleg, AY; Righi, E; Roberts, L; Rogers, BA; Tambyah, PA; Walls, G; Yilmaz, M; Zikri, A | 1 |
| Alzari, PM; Bethel, CR; Bonomo, RA; Giannini, E; Klinke, S; Llarrull, LI; Mojica, MF; Otero, LH; Palacios, AR; Taracila, MA; Vila, AJ | 1 |
| Barkan, D; Bifani, P; Meir, M | 1 |
| Blevins, AM; Juang, P; Kollef, M; Lashinsky, JN; McCammon, C; Micek, S | 1 |
| Banfi, G; Castagna, A; Ferrari, D; Locatelli, M; Premaschi, S; Ripa, M | 1 |
| Bernard, S; Lee, K; Pakyz, A; Stevens, M; Vaughan, D | 1 |
| Albanèse, J; Bornet, C; Curti, C; Fersing, C; Guinard, B; Lamy, E; Mathias, F; Primas, N; Souab, HK; Vanelle, P | 1 |
| Jacqz-Aigrain, E; Leroux, S; Magréault, S; Storme, T; Touati, J | 1 |
| Drover, DR; Elkomy, MH; Frymoyer, A; Hammer, GB; Purohit, PJ; Su, F; Sutherland, SM | 1 |
| Doogue, M; Jensen, BP; Mortensen, JS; Zhang, M | 1 |
| Al-Shaer, MH; Alghamdi, WA; Graham, E; Peloquin, CA | 1 |
| Bertsch, T; Heilmann, M; Höhl, R; Kleine, FM; Koch, S; Liebchen, U; Paal, M; Schuster, C; Steinmann, J; Vogeser, M | 1 |
| Caverly, LJ; Huang, DB; Kalikin, LM; LiPuma, JJ; Spilker, T; Stillwell, T; Young, C | 1 |
| Burnham, CD; Dantas, G; Thänert, R; Yoneda, A | 1 |
| AlAzmi, A; AlHashem, G; Jamal, W; Khodakhast, FB; Rotimi, VO; Sόki, J | 1 |
| Kächele, M; Keller, F | 1 |
| Agbeve, J; Baptista, JP; Bekos, V; Bellomo, R; Boidin, C; Brinkmann, A; Buizen, L; Castro, P; Choi, G; Cole, CL; Creteur, J; De Waele, JJ; Deans, R; Eastwood, GM; Escobar, L; Gomersall, C; Gresham, R; Jamal, JA; Joynt, GM; Kanji, S; Kluge, S; König, C; Koulouras, VP; Lassig-Smith, M; Laterre, PF; Lee, A; Lefrant, JY; Lei, K; Leung, P; Lipman, J; Llauradó-Serra, M; Martin-Loeches, I; Mat Nor, MB; Mudaliar, MY; Ostermann, M; Parker, SL; Paul, SK; Peake, SL; Rello, J; Richards, B; Roberts, DM; Roberts, JA; Roberts, MS; Rodríguez, A; Roehr, AC; Roger, C; Seoane, L; Sinnollareddy, M; Sousa, E; Soy, D; Spring, A; Starr, T; Stephens, D; Taccone, FS; Thomas, J; Turnidge, J; Ulldemolins, M; Valkonen, MM; Wallis, SC; Williams, T; Wittebole, X; Zikou, XT | 1 |
| Adams, R; Agus, A; Barnes, RA; Chau, I; Clarke, M; Coyle, V; Doran, A; Forde, C; Grayson, M; McAuley, DF; McDowell, C; McMullan, R; Plummer, R; Thomas, AL; Wilson, RH | 1 |
| Bruniera, FR; Costa, SF; Cury, AP; Higashino, H; Mendes, FR; Oliveira, FN; Rizeck, C; Rocha, V; Rossi, F; Schmidt, J | 1 |
| Delattre, IK; Dugernier, T; Hites, M; Jacobs, F; Laterre, PF; Spapen, H; Taccone, FS; Wallemacq, PE | 1 |
| Grabein, B; Liebchen, U; Paal, M; Scharf, C; Schroeder, I; Siebers, C; Zander, J; Zoller, M | 1 |
| Benken, LA; Chamberlain, AR; Jones, RL; Kaplan, JM; Murphy, ME; Stoneman, EM; Tang Girdwood, SC; Tang, PH; Vinks, AA | 1 |
| Dorn, C; Hitzenbichler, F; Kees, F; Kees, M; Liebchen, U; Paal, M; Schiesser, S | 1 |
| Al-Shaer, MH; Alghamdi, WA; Peloquin, C | 1 |
| Egge, JA; Heintz, BH; Lee, JD; Livorsi, DJ; Lund, BC; Mosher, HJ | 1 |
| Sivashanmugam, K; Srivastava, P | 1 |
| Krnáč, D; Reiffová, K; Rolinski, B | 1 |
| Charlier, C; Chouchana, L; Contejean, A; Kernéis, S; Treluyer, JM | 1 |
| Barreto, EF; Bjergum, MW; Jannetto, PJ; Rule, AD; Scheetz, MH | 1 |
| Chua, NG; Hoo, GSR; Kwa, AL; Lee, L; Ling, LM; Ng, TM | 1 |
| Becker, SL; Egle, L; Graf, N; Haber, M; Ockfen, S; Sauter, K; Simon, A; Wagenpfeil, G | 1 |
| Duong, L; Harriott, NG; Ives, AL; Pan-Chen, S; Rungkitwattanakul, D | 1 |
| Boelens, J; De Waele, JJ; Polet, M; Stove, V; Van Vooren, S; Vanhaecke, L; Verstraete, AG | 1 |
| Colman, S; De Waele, JJ; Dhaese, S; Stove, V; Verstraete, AG | 1 |
| Burgess, DS; Clark, JA; Landmesser, KB | 1 |
| Bucher, V; Irlbeck, M; Liebchen, U; Paal, M; Scharf, C; Schroeder, I; Vogeser, M; Zoller, M | 1 |
| Agarwal, SK; Buckley, MS; D'Alessio, PA; Kane-Gill, SL; Kobic, E; Komerdelj, IA; Martinez, BK; Rangan, P; Tinta, NC; Yerondopoulos, MJ; Ziadat, DS | 1 |
| Besch, G; Capellier, G; Chaignat, C; Clairet, AL; Despres, C; Floury, SP; Labro, G; Lagoutte-Renosi, J; Montange, D; Piton, G; Puyraveau, M; Vettoretti, L; Vivet, B; Winiszewski, H | 1 |
| Hess, C; Kessler, A; Schneider, H; Steimer, W | 1 |
| Chua, NG; Cove, M; Hee, DKH; Hoo, GSR; Kwa, AL; Lee, LS; Lee, W; Lim, TP; Ling, LM; Loo, L; Ng, TM; Ong, JCL; Soong, JL; Tang, SSL; Zhou, YP | 1 |
| Albur, M; Attwood, M; Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Doogue, M; Jensen, BP; Mortensen, JS | 1 |
| Ding, Y; Dong, J; Jiao, Z; Li, L; Liu, Y; Qian, J | 1 |
| Anane, S; Attou, R; Barreto Gutierrez, L; Cismas, BV; Djimafo, P; Gallerani, A; Honore, PM; Kaefer, K; Preseau, T; Redant, S | 1 |
| Liebchen, U; Scharf, C | 1 |
| Hiort, B; Hofmann, M; Hopf, HB; Kehmann, J; Kim, SH; Starl, A | 1 |
| Ardebili, A; Bagheri, H; Goharrizi, MASB; Hjimohammadi, A; Izanloo, A; Jamali, A; Shahri, FN | 1 |
| Bauer, MJ; Flora, MS; Forde, BM; Habib, ZH; Harris, P; Islam, K; Roberts, JA; Shirin, T; Sime, FB; Wallis, SC | 1 |
| Güler, N; Süleyman, A; Tamay, Z | 1 |
| Baczek, SM; Cohen, JA; Hodge, LA; Ingemi, AI; Kaplan, MC; Kiley, PS; Pearston, AP; Shaeffer, ZA; Soriano, KM; Stanley, JS; Talt, IE; Wilson, TJ; Yao, A | 1 |
| Wang, Y; Zhang, W | 1 |
| Babiak, P; Cizmarova, I; Kovac, A; Mikus, P; Parrak, V; Piestansky, J; Secnik, P | 1 |
| Gu, H; Tong, K; Wei, J; Zhou, S | 1 |
| Cheng, B; Guo, P; Jia, P; Xu, Y; Yang, Q; Zhang, H; Zhu, Y | 1 |
| Arenere-Mendoza, M; Fernández-de-Gamarra-Martínez, E; Fernández-Polo, A; González-Suárez, S; Gutiérrez-Urbón, JM; Nicolás-Picó, J; Rodríguez-Mateos, ME; Sánchez-Yáñez, E | 1 |
| Jang, SM; Lewis, SJ; Rhie, SJ | 1 |
| Cai, Q; Cao, Y; Chen, C; Gao, P; Hou, FF; Hu, Y; Johnson, DW; Kong, Y; Li, G; Li, H; Liu, B; Liu, H; Liu, X; Lu, F; Nie, S; Shen, J; Shi, Y; Su, G; Tang, Y; Wan, Q; Weng, J; Xiao, C; Xie, D; Xu, G; Xu, H; Xu, X; Yang, Q; Zha, Y; Zhou, Y | 1 |
| Béranger, A; Bille, E; Callot, D; Chouchana, L; Debray, A; Hirt, D; Oualha, M; Renolleau, S; Tréluyer, JM | 1 |
| Chai, MG; Cotta, MO; Farkas, A; Roberts, JA | 1 |
| Caljon, B; Crombé, F; De Geyter, D; Demuyser, T; Janssen, T; Muyldermans, A; Piérard, D; Seyler, L; Vanstokstraeten, R; Wybo, I | 1 |
| Abdelhaq, AI; Abutaha, SA; Aiesh, BM; Nazzal, MA; Sabateen, A; Zyoud, SH | 1 |
| Armengol de la Hoz, MÁ; Becker, CD; Calvachi-Prieto, P; Celi, LA; Chen, AY; Chen, C; Dagan, A; Deng, CY; Johnson, AEW; Khazi-Syed, A; Scurlock, C | 1 |
| Chen, CH; Ho, MW; Hsueh, PR; Ko, WC; Lin, HH; Tseng, KH; Wu, PH | 1 |
| Abdulla, A; Bahmany, S; Ewoldt, TMJ; Koch, BCP | 1 |
| Cao, SS; Cui, B; Cui, F; Cui, J; Fan, BY; Fan, TT; Guan, Y; Ji, B; Li, MY; Li, SR; Wang, JW; Wang, L; Yan, CY; Zhang, W | 1 |
| Furuya, K; Ito, K; Makio, S; Shimada, T; Sugiyama, K | 1 |
| Demuyser, T; Echahidi, F; Olbrecht, M; Peeters, C; Piérard, D; Vandamme, P; Wybo, I | 1 |
| Cotta, MO; Elhadi, M; Farkas, A; Imani, S; Kanji, S; Luque-Pardos, S; Roberts, JA; Sanches, C; Sandaradura, I; Scheetz, MH; Schellack, N; Tabah, A; Timsit, JF; Wilks, K; Williams, PG; Xie, J | 1 |
| Chen, WT; DeRyke, CA; Karlowsky, JA; Lob, SH; Motyl, MR; Sahm, DF; Siddiqui, F; Young, K | 1 |
| Arriaga-García, FJ; Medellín-Garibay, SE; Milán-Segovia, RDC; Pérez-González, LF; Rodríguez-Báez, AS; Romano-Moreno, S; Velarde-Salcedo, R | 1 |
13 review(s) available for piperacillin and meropenem
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Role of pharmacodynamics in designing dosage regimens for beta-lactams.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Dose-Response Relationship, Drug; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2003 |
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fever; Humans; Imipenem; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Thienamycins | 2010 |
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Cefpirome; Ceftazidime; Cephalosporins; Critical Illness; Humans; Imipenem; Infections; Meropenem; Piperacillin; Thienamycins | 2011 |
Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Critical Illness; Humans; Meropenem; Piperacillin; Renal Replacement Therapy; Shock, Septic; Thienamycins | 2014 |
New antibiotic dosing in infants.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; Clindamycin; Humans; Infant; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Meropenem; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Thienamycins | 2015 |
Infections caused by Tissierella praeacuta: A report of two cases and literature review.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Typing Techniques; Femoral Neck Fractures; Femur; Firmicutes; Humans; Liver Abscess; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Pseudarthrosis; Pyonephrosis; RNA, Ribosomal, 16S; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thienamycins; Treatment Outcome | 2016 |
Antibiotic Dosing in Continuous Renal Replacement Therapy.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Computer Simulation; Critical Illness; Humans; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Renal Replacement Therapy; Sepsis; Tazobactam; Thienamycins | 2017 |
[Pharmacotherapy and kidney dysfunction].
Topics: Anti-Bacterial Agents; Critical Illness; Glomerular Filtration Rate; Humans; Kidney Diseases; Meropenem; Pharmacokinetics; Piperacillin; Vancomycin | 2019 |
[Pharmacokinetics and pharmacodynamics in extracorporeal renal replacement therapy].
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Meropenem; Piperacillin; Renal Dialysis; Renal Replacement Therapy; Vancomycin | 2021 |
Capnocytophaga sputigena bloodstream infection in hematopoietic stem cell transplantations: two cases report and review of the literature.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Capnocytophaga; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Meropenem; Middle Aged; Mucositis; Neutrophils; Piperacillin; RNA, Ribosomal, 16S; Sequence Analysis, DNA; Tazobactam; Transplantation, Autologous | 2020 |
Quantification of Antibiotics in Patient Samples: State of the Art in Standardization and Proficiency Testing.
Topics: Anti-Bacterial Agents; Humans; Linezolid; Meropenem; Piperacillin; Reference Standards | 2022 |
Preanalytical Stability of Flucloxacillin, Piperacillin, Tazobactam, Meropenem, Cefalexin, Cefazolin, and Ceftazidime in Therapeutic Drug Monitoring: A Structured Review.
Topics: Anti-Bacterial Agents; Cefazolin; Ceftazidime; Cephalexin; Drug Monitoring; Drug Stability; Floxacillin; Humans; Meropenem; Piperacillin; Tazobactam | 2022 |
15 trial(s) available for piperacillin and meropenem
| Article | Year |
|---|---|
Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Topics: Amikacin; Anti-Bacterial Agents; Drug Therapy, Combination; Fever; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Hematologic Neoplasms; Humans; Infections; Meropenem; Neoplasms; Netilmicin; Neutropenia; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2004 |
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Male; Meropenem; Middle Aged; Neoplasms; Neutropenia; Opportunistic Infections; Penicillanic Acid; Piperacillin; Prospective Studies; Tazobactam; Thienamycins | 2005 |
Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
Topics: Adolescent; Adult; Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fever; Humans; Immunocompromised Host; Male; Meropenem; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Prospective Studies; Risk Assessment; Risk Factors; Tazobactam; Thienamycins | 2006 |
Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amikacin; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Critical Illness; Drug Monitoring; Female; Humans; Male; Meropenem; Metabolic Clearance Rate; Middle Aged; Models, Biological; Piperacillin; Sepsis; Thienamycins; Tissue Distribution; Treatment Outcome | 2012 |
Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Cephalosporins; Cohort Studies; Cross Infection; Drug Administration Schedule; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hospitals, Teaching; Hospitals, Urban; Humans; Infusions, Intravenous; Intensive Care Units; Length of Stay; Male; Meropenem; Middle Aged; Missouri; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2013 |
Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Female; Humans; Japan; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prospective Studies; Statistics, Nonparametric; Thienamycins; Treatment Outcome | 2013 |
Antibiotic rotation for febrile neutropenic patients with hematological malignancies: clinical significance of antibiotic heterogeneity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactam Resistance; Cefepime; Cephalosporins; Ciprofloxacin; Drug Administration Schedule; Female; Fever; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Male; Meropenem; Middle Aged; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2013 |
Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial.
Topics: beta-Lactamase Inhibitors; Creatine; Critical Illness; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2014 |
Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime.
Topics: Age Factors; Aged; Anti-Bacterial Agents; APACHE; Candidiasis, Invasive; Cefuroxime; Ciprofloxacin; Critical Illness; Denmark; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Single-Blind Method; Thienamycins | 2015 |
Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Clinical Protocols; Drug Resistance, Microbial; Escherichia coli Infections; Humans; Klebsiella Infections; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sample Size; Thienamycins | 2015 |
A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Chemotherapy-Induced Febrile Neutropenia; Child; Child, Preschool; Female; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2017 |
Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Child; Child, Preschool; Febrile Neutropenia; Female; Humans; Immunoglobulins, Intravenous; Infant; Infant, Newborn; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Young Adult | 2018 |
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Boronic Acids; Drug Combinations; Female; Humans; Intention to Treat Analysis; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Pyelonephritis; Thienamycins; Urinary Tract Infections; Urine | 2018 |
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteremia; Cause of Death; Ceftriaxone; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2018 |
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Cost-Benefit Analysis; Drug Administration Schedule; Equivalence Trials as Topic; Humans; Meropenem; Multicenter Studies as Topic; Neoplasms; Neutropenia; Piperacillin; Pragmatic Clinical Trials as Topic; Quality of Life; Sepsis; Tazobactam; Treatment Outcome | 2020 |
315 other study(ies) available for piperacillin and meropenem
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests | 2007 |
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Longitudinal Studies; Pneumonia, Ventilator-Associated; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.
Topics: beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Hydrolysis; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2007 |
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Microbial Sensitivity Tests; Middle Aged; Portugal | 2007 |
Spread in an Italian hospital of a clonal Acinetobacter baumannii strain producing the TEM-92 extended-spectrum beta-lactamase.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cross Infection; Humans; Italy; Microbial Sensitivity Tests | 2007 |
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Critical Illness; Endemic Diseases; Female; Gastrointestinal Tract; Humans; Imipenem; Incidence; Intensive Care Units; Male; Middle Aged; Pharynx; Pseudomonas aeruginosa; Pseudomonas Infections; Rectum; Risk Factors | 2007 |
Identification of the novel narrow-spectrum beta-lactamase SCO-1 in Acinetobacter spp. from Argentina.
Topics: Acinetobacter; Acinetobacter Infections; Amino Acid Sequence; Anti-Bacterial Agents; Argentina; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Clavulanic Acid; Cloning, Molecular; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Sequence Analysis, DNA | 2007 |
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Bacterial; Ethidium; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Minocycline; Molecular Sequence Data; Sequence Analysis, DNA; Tigecycline | 2007 |
blaVIM-2-harboring integrons isolated in India, Russia, and the United States arise from an ancestral class 1 integron predating the formation of the 3' conserved sequence.
Topics: Base Sequence; beta-Lactamases; DNA Transposable Elements; Evolution, Molecular; Genes, Bacterial; Humans; India; Integrons; Molecular Sequence Data; Pseudomonas aeruginosa; Russia; United States | 2007 |
Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome.
Topics: Bacteremia; Community-Acquired Infections; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae Infections; Gene Transfer, Horizontal; Humans; Infectious Disease Transmission, Professional-to-Patient; Integrons; Microbial Sensitivity Tests; Nucleic Acid Amplification Techniques; Polymerase Chain Reaction; Prospective Studies; Risk Factors; Sequence Analysis, DNA; Treatment Outcome | 2007 |
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Cephalosporins; Chryseobacterium; Flavobacteriaceae Infections; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Sequence Analysis, DNA | 2007 |
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
Topics: Acinetobacter; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Brazil; Codon, Terminator; Cross Infection; Drug Resistance, Multiple, Bacterial; Gene Transfer, Horizontal; Genes, Bacterial; Hospitals; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Open Reading Frames; Plasmids; Pseudomonas putida; Transcription, Genetic | 2007 |
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Hospitals; Humans; Israel; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology | 2007 |
Molecular epidemiology of imipenem-resistant Acinetobacter haemolyticus and Acinetobacter baumannii isolates carrying plasmid-mediated OXA-40 from a Portuguese hospital.
Topics: Acinetobacter; Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; beta-Lactamases; Cross Infection; Humans; Plasmids; Portugal | 2007 |
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
Topics: Bacterial Proteins; Base Sequence; beta-Lactamases; Carrier Proteins; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Genes, MDR; Genetic Vectors; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Porins | 2007 |
Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ceftazidime; Colony Count, Microbial; DNA, Bacterial; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Genotype; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Mutation; Phenotype; Porins; Pseudomonas aeruginosa; Reverse Transcriptase Polymerase Chain Reaction; Thienamycins | 2007 |
An OXA-66/OXA-51-like carbapenemase and possibly an efflux pump are associated with resistance to imipenem in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; Base Sequence; beta-Lactamases; Drug Resistance, Bacterial; Electrophoresis, Gel, Two-Dimensional; Electrophoresis, Polyacrylamide Gel; Gene Expression Regulation, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Homology, Nucleic Acid | 2007 |
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
Topics: Aztreonam; beta-Lactamases; Carbapenems; Catalysis; Cephalosporins; Clavulanic Acid; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Hydrolysis; Kinetics; Molecular Weight; Penicillanic Acid; Penicillins; Recombinant Proteins; Serratia; Sulbactam; Tazobactam | 2007 |
First occurrence of an IMP metallo-beta-lactamase in Aeromonas caviae: IMP-19 in an isolate from France.
Topics: Aeromonas; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; France; Integrons; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA; Substrate Specificity | 2007 |
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenems; Chromosomes, Bacterial; Cross Infection; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Integrons; Molecular Epidemiology; Molecular Sequence Data; Mutation; Plasmids; Polymerase Chain Reaction; Porins; Pseudomonas aeruginosa; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Spain | 2007 |
Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; Female; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids | 2008 |
Induction of L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Catechol 2,3-Dioxygenase; Enzyme Induction; Gene Expression Regulation, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Sequence Analysis, DNA; Stenotrophomonas maltophilia | 2008 |
Induction of L1 and L2 beta-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Enzyme Induction; Gene Expression Regulation, Bacterial; Genes, Regulator; Humans; Mutation; Stenotrophomonas maltophilia | 2008 |
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Brachyspira; Cloning, Molecular; Diarrhea; Feces; Gram-Negative Bacterial Infections; Humans; Kinetics; Molecular Sequence Data; Oxacillin; Penicillin Resistance; Sequence Analysis, DNA | 2008 |
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
Topics: Base Sequence; beta-Lactamases; beta-Lactams; Cloning, Molecular; Colombia; DNA Transposable Elements; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; United States | 2008 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.
Topics: Bacterial Proteins; beta-Lactamases; Canada; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Gentamicins; Humans; Intensive Care Units; Microbial Sensitivity Tests | 2008 |
Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Carbapenems; China; Conjugation, Genetic; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Hospitals, University; Humans; Hydrolysis; Intensive Care Units; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Serratia marcescens | 2008 |
IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.
Topics: Adult; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Hospitals; Humans; Imipenem; Kentucky; Male; Mexico; Pseudomonas aeruginosa; United States | 2008 |
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.
Topics: Aged; Bacterial Proteins; Base Sequence; beta-Lactamases; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Quinolones; United States | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Functional diversity among metallo-beta-lactamases: characterization of the CAR-1 enzyme of Erwinia carotovora.
Topics: Amino Acid Sequence; Bacterial Proteins; Base Sequence; beta-Lactamases; Cloning, Molecular; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Molecular Sequence Data; Open Reading Frames; Pectobacterium carotovorum; Phenotype; Phylogeny; Recombinant Proteins; Sequence Homology, Amino Acid | 2008 |
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Mexico; Models, Genetic; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Characterization of the carbapenem-hydrolyzing oxacillinase oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Sequence Analysis, DNA | 2008 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Genetic; Turkey | 2008 |
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates.
Topics: Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Ciprofloxacin; Drug Resistance, Bacterial; Enterobacter cloacae; Genes, Bacterial; Microbial Sensitivity Tests; Plasmids; Quinolones | 2008 |
VIM-15 and VIM-16, two new VIM-2-like metallo-beta-lactamases in Pseudomonas aeruginosa isolates from Bulgaria and Germany.
Topics: Amino Acid Substitution; Bacterial Proteins; beta-Lactamases; Bulgaria; Catalysis; Germany; Hydrolysis; Isoenzymes; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Sequence Analysis, DNA | 2008 |
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
Topics: Acremonium; Bacterial Proteins; beta-Lactamases; Catalysis; Catalytic Domain; Cefepime; Ceftazidime; Cephalosporins; Kinetics; Models, Molecular; Mutation; Penicillinase; Protein Structure, Tertiary; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2008 |
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Blood; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Taiwan | 2008 |
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Cloning, Molecular; DNA Primers; DNA, Bacterial; Genes, Bacterial; Genetic Variation; Humans; Imipenem; Integrons; Kinetics; Meropenem; Molecular Sequence Data; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Sequence Homology, Amino Acid; Spain; Thienamycins | 2008 |
Plasmid-encoded carbapenem-hydrolyzing beta-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from Belgium.
Topics: Adult; Anti-Bacterial Agents; Belgium; beta-Lactamases; beta-Lactams; Carbapenems; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Plasmids | 2008 |
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroquinolones; Genes, Bacterial; Humans; In Vitro Techniques; Meropenem; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2008 |
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Cross Infection; Enterocolitis, Pseudomembranous; Glycosides; Humans; In Vitro Techniques; Microbial Sensitivity Tests | 2008 |
A plasmid-borne blaOXA-58 gene confers imipenem resistance to Acinetobacter baumannii isolates from a Lebanese hospital.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Conjugation, Genetic; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Hospitals, University; Humans; Imipenem; Lebanon; Molecular Epidemiology; Molecular Sequence Data; Plasmids | 2008 |
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
Topics: Amino Acid Sequence; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Citrobacter freundii; Conjugation, Genetic; DNA Primers; DNA, Bacterial; Enterobacteriaceae Infections; Escherichia coli K12; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Recombinant Proteins; Sequence Homology, Amino Acid | 2008 |
In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.
Topics: Anti-Bacterial Agents; Carbapenems; Doripenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; United States | 2008 |
High prevalence of plasmid-mediated quinolone resistance genes qnr and aac(6')-Ib-cr in clinical isolates of Enterobacteriaceae from nine teaching hospitals in China.
Topics: Acetyltransferases; Anti-Bacterial Agents; Bacterial Proteins; China; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals, Teaching; Humans; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Prevalence; Quinolones | 2008 |
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.
Topics: Base Sequence; beta-Lactam Resistance; beta-Lactamases; Data Collection; DNA Primers; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Integrons; Italy; Molecular Epidemiology; Molecular Sequence Data | 2008 |
In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Carbapenems; Doripenem; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests | 2008 |
KPC-2-producing Enterobacter cloacae and pseudomonas putida coinfection in a liver transplant recipient.
Topics: Anti-Bacterial Agents; beta-Lactamases; Enterobacter cloacae; Female; Humans; Liver Transplantation; Microbial Sensitivity Tests; Middle Aged; Pseudomonas putida; RNA, Ribosomal, 16S | 2009 |
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
Topics: Amino Acid Sequence; beta-Lactamases; Blotting, Southern; Ceftazidime; Cephalosporins; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Homology, Amino Acid; Shigella sonnei | 2009 |
Detection of the pandemic O25-ST131 human virulent Escherichia coli CTX-M-15-producing clone harboring the qnrB2 and aac(6')-Ib-cr genes in a dog.
Topics: Animals; Anti-Bacterial Agents; Dogs; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Humans; Plasmids; Virulence | 2009 |
Codetection of blaOXA-23-like gene (blaOXA-133) and blaOXA-58 in Acinetobacter radioresistens: report from the SENTRY antimicrobial surveillance program.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Bacterial; Molecular Sequence Data; Plasmids; Population Surveillance; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2009 |
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
Topics: beta-Lactamases; Brazil; Carbapenems; Klebsiella pneumoniae | 2009 |
Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Clavulanic Acid; Drug Resistance, Bacterial; Enzyme Inhibitors; Genetic Variation; Hydrolysis; Isoelectric Focusing; Klebsiella pneumoniae; Microbial Sensitivity Tests; Phenotype; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Genetic variability among ampC genes from acinetobacter genomic species 3.
Topics: Acinetobacter; Acinetobacter baumannii; Amino Acid Sequence; Ampicillin Resistance; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; Escherichia coli; Genes, Bacterial; Genetic Variation; Humans; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Spain | 2009 |
Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.
Topics: Alleles; Amino Acid Sequence; Amino Acid Substitution; Base Sequence; beta-Lactamases; Burkholderia cepacia complex; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Hydrolysis; Isoelectric Point; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2009 |
Carbapenem resistance among Pseudomonas aeruginosa strains from India: evidence for nationwide endemicity of multiple metallo-beta-lactamase clones (VIM-2, -5, -6, and -11 and the newly characterized VIM-18).
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; India; Microbial Sensitivity Tests; Molecular Sequence Data; Prevalence; Pseudomonas aeruginosa; Ribotyping | 2009 |
blaCTX-M genes in escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures.
Topics: Base Sequence; beta-Lactamases; DNA Transposable Elements; Escherichia coli; Molecular Sequence Data; Plasmids; Polymerase Chain Reaction | 2009 |
Surveillance of carbapenem-resistant Pseudomonas aeruginosa isolates from Puerto Rican Medical Center Hospitals: dissemination of KPC and IMP-18 beta-lactamases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Outer Membrane Proteins; beta-Lactamases; Carbapenems; Child; Child, Preschool; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Female; Humans; Infant; Male; Membrane Transport Proteins; Microbial Sensitivity Tests; Middle Aged; Polymerase Chain Reaction; Porins; Pseudomonas aeruginosa | 2009 |
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
Topics: Austria; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2009 |
Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Ceftazidime; Cephalosporinase; Humans; Imipenem; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Sequence Analysis, DNA | 2009 |
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
Topics: Acetylation; Acetyltransferases; Aminoglycosides; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2009 |
AbaR5, a large multiple-antibiotic resistance region found in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Base Sequence; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Molecular Sequence Data; Multigene Family; Polymerase Chain Reaction | 2009 |
AmpDI is involved in expression of the chromosomal L1 and L2 beta-lactamases of Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Genome, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction; Stenotrophomonas maltophilia | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity.
Topics: Anti-Bacterial Agents; Benzofurans; Enoyl-(Acyl-Carrier-Protein) Reductase (NADH); Enterobacteriaceae; Enterococcus; Microbial Sensitivity Tests; Moraxella catarrhalis; Pyrones; Staphylococcal Infections; Staphylococcus; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae | 2009 |
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
Topics: Amino Acid Sequence; Amoxicillin; Ampicillin; Animals; Anti-Bacterial Agents; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Blotting, Southern; Campylobacter jejuni; Carbenicillin; Cephalosporins; Chickens; Cloxacillin; Isoelectric Focusing; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Piperacillin; Polymerase Chain Reaction; Sequence Alignment; Ticarcillin | 2009 |
Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Klebsiella pneumoniae; Polymerase Chain Reaction | 2009 |
Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Carbapenems; Ceftazidime; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones | 2009 |
Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Poland.
Topics: Anti-Bacterial Agents; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Molecular Sequence Data; Poland | 2009 |
New variant of CTX-M-type extended-spectrum beta-lactamases, CTX-M-71, with a Gly238Cys substitution in a Klebsiella pneumoniae isolate from Bulgaria.
Topics: Anti-Bacterial Agents; beta-Lactamases; Bulgaria; Cefepime; Cefotaxime; Ceftazidime; Cephalosporins; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data | 2009 |
Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China.
Topics: Anti-Bacterial Agents; beta-Lactamases; Blotting, Southern; Carbapenems; China; Electrophoresis, Gel, Pulsed-Field; Enterobacteriaceae; Microbial Sensitivity Tests; Polymerase Chain Reaction | 2009 |
Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Genotype; Microbial Sensitivity Tests; Polymyxin B; Promoter Regions, Genetic; Pseudomonas aeruginosa; Transcription Factors | 2009 |
Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone re
Topics: Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Haemophilus influenzae; Microbial Sensitivity Tests; Mutation | 2009 |
IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso.
Topics: Adult; Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Ceftazidime; Cephalexin; Cephalosporins; Cephalothin; Chryseobacterium; Female; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Protein Structure, Secondary; Sequence Homology, Amino Acid | 2009 |
Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone.
Topics: beta-Lactamases; Computational Biology; Escherichia coli; Models, Genetic; Molecular Sequence Data; Open Reading Frames; Plasmids; United Kingdom | 2009 |
Nosocomial spread of colistin-only-sensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain.
Topics: Anti-Bacterial Agents; Base Sequence; beta-Lactamases; Colistin; Cross Infection; Humans; Molecular Sequence Data; Pseudomonas aeruginosa | 2009 |
Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Carboxylic Ester Hydrolases; Cefotaxime; Cefuroxime; Cephalosporins; Cephalothin; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; India; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2009 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Drug Resistance, Multiple, Bacterial; Escherichia coli; Imipenem; Meropenem; Molecular Sequence Data; Oxacillin; Penicillins; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Thienamycins | 2009 |
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Female; Humans; Mice; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Susceptibilities of 23 Desulfovibrio isolates from humans.
Topics: Ampicillin; Anti-Bacterial Agents; Chloramphenicol; Clindamycin; Desulfovibrio; Fluoroquinolones; Humans; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2009 |
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
Topics: Acinetobacter baumannii; beta-Lactamases; DNA, Bacterial; Escherichia coli; France; Genes, Bacterial; Water Microbiology | 2010 |
Novel ambler class A carbapenem-hydrolyzing beta-lactamase from a Pseudomonas fluorescens isolate from the Seine River, Paris, France.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Blotting, Southern; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; France; Fresh Water; Gram-Negative Bacteria; Health Surveys; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Pseudomonas fluorescens; Water Microbiology | 2010 |
Novel VIM metallo-beta-lactamase variant from clinical isolates of Enterobacteriaceae from Algeria.
Topics: Algeria; Anti-Bacterial Agents; Base Sequence; beta-Lactamases; beta-Lactams; Carbapenems; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Genome, Bacterial; Hospitals, Military; Imipenem; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Phenotype | 2010 |
VIM-19, a metallo-beta-lactamase with increased carbapenemase activity from Escherichia coli and Klebsiella pneumoniae.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Cloning, Molecular; DNA, Bacterial; Escherichia coli; Isoelectric Focusing; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Plasmids; Protein Conformation; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
Spread of OXA-48-encoding plasmid in Turkey and beyond.
Topics: Anti-Bacterial Agents; Belgium; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA Transposable Elements; Egypt; Enterobacteriaceae; Enterobacteriaceae Infections; France; Humans; Lebanon; Microbial Sensitivity Tests; Plasmids; Turkey | 2010 |
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Cross Infection; Humans; Intensive Care Units; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
Topics: Aeromonas; Animals; Base Sequence; beta-Lactamases; DNA Primers; DNA, Bacterial; Genes, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Paris; Water Microbiology | 2010 |
Genetic basis of multidrug resistance in Acinetobacter clinical isolates in Taiwan.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aminoglycosides; beta-Lactamases; Carbapenems; Cephalosporins; DNA Gyrase; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Taiwan | 2010 |
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
Topics: Aged; beta-Lactamases; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Klebsiella Infections; Klebsiella pneumoniae; Male; Renal Dialysis; Republic of Korea | 2010 |
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008.
Topics: Academic Medical Centers; Bacterial Proteins; Base Sequence; beta-Lactamases; Carbapenems; DNA Primers; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Escherichia coli; Escherichia coli Infections; Humans; In Vitro Techniques; Israel; Microbial Sensitivity Tests; Molecular Epidemiology; Plasmids; Time Factors | 2010 |
Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
Topics: Amino Acid Sequence; Bacterial Proteins; Base Sequence; beta-Lactamases; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Integrons; Middle Aged; Molecular Sequence Data; Netherlands; Pseudomonas Infections; Pseudomonas stutzeri; Sequence Homology, Amino Acid; Substrate Specificity | 2010 |
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Drug Resistance, Bacterial; Humans; Israel; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Epidemiology; Phylogeny; Plasmids; Polymerase Chain Reaction | 2010 |
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
Topics: Acinetobacter; Acinetobacter Infections; beta-Lactam Resistance; beta-Lactamases; Cephalosporinase; Gene Transfer, Horizontal; Genes, Bacterial; Humans; In Vitro Techniques; Integrons; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Phylogeny; Taiwan | 2010 |
AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia.
Topics: Bacterial Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; DNA Primers; Escherichia coli; Gene Dosage; Gene Expression; Genes, Bacterial; Genetic Complementation Test; Membrane Transport Proteins; Molecular Sequence Data; Mutation; Operon; Promoter Regions, Genetic; Stenotrophomonas maltophilia | 2010 |
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
Topics: Acinetobacter baumannii; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Dibekacin; Hospitals, Military; Humans; Microbial Sensitivity Tests; Warfare | 2010 |
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Topics: Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cephalosporinase; Clavulanic Acid; Computer Simulation; Enzyme Inhibitors; Hydrogen Bonding; Kinetics; Microbial Sensitivity Tests; Molecular Structure; Mutagenesis, Site-Directed; Penicillanic Acid; Protein Structure, Secondary; Spectrometry, Mass, Electrospray Ionization; Substrate Specificity; Sulbactam; Tazobactam | 2010 |
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Drug Resistance, Bacterial; Germany; Hospitals, University; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.
Topics: Ampicillin; Ampicillin Resistance; Anti-Bacterial Agents; beta-Lactamases; DNA Mutational Analysis; Enzyme Stability; Escherichia coli; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Protein Conformation; Protein Folding; Structure-Activity Relationship | 2010 |
Contribution of a plasmid-borne blaOXA-58 gene with its hybrid promoter provided by IS1006 and an ISAba3-like element to beta-lactam resistance in acinetobacter genomic species 13TU.
Topics: Acinetobacter; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Carbapenems; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Promoter Regions, Genetic; Recombination, Genetic; Sequence Analysis, DNA; Species Specificity; Tazobactam | 2010 |
Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; beta-Lactamases; Child; Child, Preschool; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; Sweden; Travel; White People; Young Adult | 2010 |
Complete nucleotide sequence of Klebsiella pneumoniae multidrug resistance plasmid pKP048, carrying blaKPC-2, blaDHA-1, qnrB4, and armA.
Topics: Aminoglycosides; Anti-Bacterial Agents; Base Sequence; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Klebsiella pneumoniae; Models, Genetic; Molecular Sequence Data; Plasmids | 2010 |
Extended-spectrum cephalosporinase in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Amino Acid Sequence; Amino Acid Substitution; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporin Resistance; Cephalosporinase; Cephalosporins; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Monobactams; Mutagenesis, Site-Directed | 2010 |
NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Ceftazidime; Microbial Sensitivity Tests; Mutation; N-Acetylmuramoyl-L-alanine Amidase; Pseudomonas aeruginosa; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Anaerobic; Bacteroides fragilis; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Positive Cocci; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Republic of Korea | 2010 |
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Colistin; Drug Resistance, Multiple, Bacterial; Microbial Sensitivity Tests; Mutation | 2010 |
An ertapenem-resistant extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae clone carries a novel OmpK36 porin variant.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Electrophoresis, Polyacrylamide Gel; Ertapenem; Imipenem; Klebsiella pneumoniae; Meropenem; Molecular Sequence Data; Porins; Thienamycins | 2010 |
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
Topics: Ampicillin; beta-Lactamases; Computational Biology; Escherichia coli; Hydrogen Bonding; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Protein Structure, Secondary; Ticarcillin | 2010 |
High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.
Topics: beta-Lactamases; Bradyrhizobium; Crystallography, X-Ray; Molecular Sequence Data; Protein Structure, Secondary; Substrate Specificity; Sulfonamides | 2010 |
Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Blotting, Southern; Carbapenems; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Molecular Sequence Data; Plasmids; Taiwan | 2010 |
Emergence of metallo-β-lactamase NDM-1-producing multidrug-resistant Escherichia coli in Australia.
Topics: Anti-Bacterial Agents; Australia; beta-Lactamases; beta-Lactams; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Methyltransferases; Microbial Sensitivity Tests; Polymerase Chain Reaction | 2010 |
Microbiologic and clinical implications of bacteremia due to extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC beta-lactamase DHA-1.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Carbapenems; Case-Control Studies; Ciprofloxacin; Female; Humans; Klebsiella pneumoniae; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Young Adult | 2010 |
Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC beta-lactamase overproduction and outer membrane protein loss.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Blotting, Southern; Drug Resistance, Bacterial; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; Porins; Reverse Transcriptase Polymerase Chain Reaction; Serratia Infections; Serratia marcescens; Thienamycins; Young Adult | 2010 |
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Fatal Outcome; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Disease Models, Animal; Female; Klebsiella Infections; Klebsiella pneumoniae; Mice; Microbial Sensitivity Tests; Sepsis | 2011 |
Genetic context and biochemical characterization of the IMP-18 metallo-beta-lactamase identified in a Pseudomonas aeruginosa isolate from the United States.
Topics: Amino Acid Sequence; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ertapenem; Meropenem; Microbial Sensitivity Tests; Models, Genetic; Molecular Sequence Data; Open Reading Frames; Pseudomonas aeruginosa; Sequence Homology, Amino Acid; Thienamycins; United States | 2011 |
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; K562 Cells; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship | 2017 |
Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; CHO Cells; Cricetulus; Drug Stability; Escherichia coli; Female; Humans; Meropenem; Mice; Microbial Sensitivity Tests; Molecular Structure; Monobactams; Pseudomonas aeruginosa; Receptors, GABA-A; Seizures; Structure-Activity Relationship; Thienamycins | 2018 |
Microwave-assisted solid-phase synthesis of antisense acpP peptide nucleic acid-peptide conjugates active against colistin- and tigecycline-resistant E. coli and K. pneumoniae.
Topics: Anti-Bacterial Agents; Colistin; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Escherichia coli; Klebsiella pneumoniae; Microbial Sensitivity Tests; Microwaves; Molecular Structure; Peptide Nucleic Acids; Peptides; Solid-Phase Synthesis Techniques; Structure-Activity Relationship; Tigecycline | 2019 |
Nitroxoline and its derivatives are potent inhibitors of metallo-β-lactamases.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Nitroquinolines; Recombinant Proteins; Structure-Activity Relationship | 2022 |
Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacteroides fragilis; Cefoxitin; Clindamycin; Drug Resistance, Microbial; Imipenem; Meropenem; Metronidazole; Microbial Sensitivity Tests; Piperacillin; Sulbactam; Thienamycins | 1993 |
The new antibiotics, 1997.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Erythromycin; Fluoroquinolones; Humans; Macrolides; Meropenem; Penicillins; Piperacillin; Quinolones; Thienamycins | 1997 |
Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Ciprofloxacin; Clinical Trials as Topic; Drug Resistance, Microbial; Gentamicins; Humans; Imipenem; Isoelectric Focusing; Meropenem; Microbial Sensitivity Tests; Penicillins; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Tobramycin | 1997 |
Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.
Topics: Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bacteroides fragilis; Ciprofloxacin; Clindamycin; Drug Therapy, Combination; Fluoroquinolones; Hydrogen-Ion Concentration; Imipenem; Meropenem; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 1997 |
Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Drug Synergism; Enzyme Inhibitors; Imipenem; Meropenem; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Tazobactam; Thienamycins | 1997 |
[The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum].
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefozopran; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Monobactams; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serotyping; Sputum; Thienamycins | 1998 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
[Susceptibility of clinical strains of gram-positive bacteria to selected beta-lactam antibiotics].
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Clavulanic Acids; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Species Specificity; Thienamycins; Ticarcillin | 1998 |
Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
Topics: Burkholderia cepacia; Burkholderia Infections; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Synergism; Drug Therapy, Combination; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillins; Piperacillin; Rifampin; Thienamycins; Tobramycin | 1999 |
In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Ceftazidime; Drug Combinations; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1999 |
[In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998].
Topics: Bacteria; Carbapenems; Ceftazidime; Cephalosporins; Drug Resistance, Microbial; Humans; Imipenem; Meropenem; Penicillins; Piperacillin; Respiratory Tract Infections; Thienamycins; Time Factors | 1999 |
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Ceftazidime; Colistin; Drug Synergism; Magainins; Meropenem; Peptides; Piperacillin; Proteins; Stenotrophomonas maltophilia; Thienamycins; Xenopus Proteins | 2000 |
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins | 2002 |
[Extended-spectrum beta-lactamase detection in Enterobacteriaceae and antibiotic susceptibility analysis].
Topics: Anti-Bacterial Agents; beta-Lactamases; Enterobacteriaceae; Escherichia coli; Humans; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillins; Piperacillin; Thienamycins | 2002 |
In vitro activity of gatifloxacin alone and in combination with cefepime, meropenem, piperacillin and gentamicin against multidrug-resistant organisms.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Cefepime; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Fluoroquinolones; Gatifloxacin; Gentamicins; Meropenem; Microbial Sensitivity Tests; Penicillins; Piperacillin; Thienamycins | 2003 |
A case of recurrent acute generalized exanthematous pustulosis due to beta-lactam antibiotics: a case report.
Topics: Acute Disease; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Diabetes Mellitus; Diagnosis, Differential; Exanthema; Hepatitis, Alcoholic; Humans; Male; Meropenem; Middle Aged; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Thienamycins | 2003 |
In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Interactions; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2003 |
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Culture Media, Conditioned; Drug Resistance, Bacterial; Humans; In Vitro Techniques; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tazobactam; Thienamycins | 2004 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2004 |
[Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Intensive Care Units; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2004 |
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; Ticarcillin | 2004 |
Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Topics: Anti-Bacterial Agents; beta-Lactams; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2005 |
Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Thienamycins | 2005 |
Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Topics: Anti-Bacterial Agents; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Dose-Response Relationship, Drug; Drug Combinations; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Population Surveillance; Prevalence; Soft Tissue Infections; Thienamycins | 2005 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
Prospective drug utilization evaluation of three broad-spectrum antimicrobials: cefepime, piperacillin-tazobactam and meropenem.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Utilization Review; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2006 |
Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftazidime; Colistin; Dose-Response Relationship, Drug; Drug Synergism; In Vitro Techniques; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Mutation; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins; Tobramycin | 2006 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
Topics: Amikacin; Anti-Infective Agents; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Meropenem; Oxazines; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Urine | 2006 |
Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.
Topics: beta-Lactamases; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Endocarditis, Bacterial; Female; Heart Valve Prosthesis; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prosthesis-Related Infections; Thienamycins | 2006 |
Evaluating broad-spectrum antimicrobials.
Topics: Animals; Anti-Bacterial Agents; Cefepime; Cephalosporins; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2006 |
Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Drug Interactions; Ertapenem; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2007 |
Use of cefepime for the treatment of infections caused by extended spectrum: beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Hospitals, Urban; Humans; India; Intensive Care Units; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Thienamycins | 2007 |
Cefepime restriction improves gram-negative overall resistance patterns in neonatal intensive care unit.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Infant, Newborn; Infant, Premature; Intensive Care Units, Neonatal; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Time Factors | 2007 |
[The frequency of PER-1 type extended spectrum beta-lactamases in nosocomial isolates of Pseudomonas aeruginosa].
Topics: Anti-Bacterial Agents; beta-Lactamases; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2007 |
Simultaneous determination of five beta-lactam antibiotics (cefepim, ceftazidim, cefuroxim, meropenem and piperacillin) in human plasma by high-performance liquid chromatography with ultraviolet detection.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cefuroxime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Stability; Humans; Meropenem; Piperacillin; Quality Control; Reproducibility of Results; Sensitivity and Specificity; Thienamycins | 2008 |
[Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Bacteriological Techniques; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Thienamycins; Wound Infection | 2009 |
Mortality rate in neonates infected with extended-spectrum beta lactamase-producing Klebsiella species and selective empirical use of meropenem.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cohort Studies; Drug Administration Schedule; Female; Humans; Infant, Newborn; Klebsiella; Klebsiella Infections; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pregnancy; Regression Analysis; Retrospective Studies; Risk Factors; Survival Analysis; Thienamycins | 2009 |
Clinical significance of cerebrospinal fluid inhibitory titers of antibiotics, based on pharmacokinetic/pharmacodynamic parameters, in the treatment of bacterial meningitis.
Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infant; Infant, Newborn; Meningitis, Bacterial; Meropenem; Microbial Sensitivity Tests; Piperacillin; Thienamycins | 2009 |
Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran hospitals.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefotaxime; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Humans; Imipenem; Iran; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2009 |
Comparative in vitro study of the antimicrobial activities of different commercial antibiotic products for intravenous administration.
Topics: Animals; Anti-Bacterial Agents; Bacteria; beta-Lactamase Inhibitors; Campylobacter Infections; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Infusions, Intravenous; Injections, Intravenous; Meropenem; Mice; Mice, Inbred BALB C; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins; Tissue Distribution | 2010 |
Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.
Topics: Anti-Bacterial Agents; Bacteremia; France; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Thienamycins; Wound Infection | 2010 |
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Sepsis; Shock, Septic; Tazobactam; Thienamycins | 2010 |
Importance of infusion volume and pump characteristics in extended administration of ß-lactam antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Administration Routes; Humans; Meropenem; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins | 2010 |
Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Cost-Benefit Analysis; Critical Care; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Male; Markov Chains; Meropenem; Middle Aged; Models, Economic; Penicillanic Acid; Piperacillin; Pneumonia; Quality-Adjusted Life Years; Tazobactam; Thienamycins; Treatment Failure; United Kingdom | 2012 |
AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
Topics: Aztreonam; Bacterial Proteins; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Membrane Transport Proteins; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2011 |
Changes in antibiotic distribution due to pancreatitis.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Male; Meropenem; Organotin Compounds; Pancreatitis; Piperacillin; Rats; Rats, Wistar; Thienamycins | 2011 |
The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey.
Topics: Acinetobacter; Anti-Bacterial Agents; Cefepime; Ceftazidime; Ceftriaxone; Cephalosporins; Cost Savings; Cross Infection; Drug Costs; Drug Prescriptions; Drug Resistance, Bacterial; Drug Utilization; Escherichia; Health Policy; Hospitals; Humans; Imipenem; Klebsiella; Meropenem; Methicillin Resistance; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Staphylococcus aureus; Teicoplanin; Thienamycins; Turkey; Vancomycin | 2011 |
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Dose-Response Relationship, Drug; Female; Humans; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Prospective Studies; Pseudomonas aeruginosa; Renal Replacement Therapy; Shock, Septic; Thienamycins | 2011 |
Necrotic intramuscular chloroma with infection: magnetic resonance imaging features.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Child; Contrast Media; Cytarabine; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Gentamicins; Humans; Image Enhancement; Klebsiella Infections; Klebsiella pneumoniae; Leg; Leukemia, Myeloid, Acute; Magnetic Resonance Imaging; Male; Meropenem; Muscle Neoplasms; Necrosis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sarcoma, Myeloid; Teicoplanin; Thienamycins; Treatment Outcome | 2011 |
Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Drug Utilization; Health Policy; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Policy; Pseudomonas aeruginosa; Switzerland; Thienamycins; Time Factors | 2012 |
First-line treatment with cephalosporins in spontaneous bacterial peritonitis provides poor antibiotic coverage.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Cephalosporins; Denmark; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Meropenem; Middle Aged; Mycoses; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2012 |
Comparative assessment of antimicrobial usage measures in the Department of Veterans Affairs.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Utilization Review; Hospitals, Veterans; Humans; Imipenem; Meropenem; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins; United States; Vancomycin | 2012 |
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltration; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins; Vancomycin | 2012 |
Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis.
Topics: Acute Disease; Anti-Bacterial Agents; Drug Interactions; Drug Therapy, Combination; Humans; Male; Meropenem; Middle Aged; Nephritis, Interstitial; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2012 |
Characteristics of initial compared with subsequent bacterial infections among hospitalised haemato-oncological patients.
Topics: Adult; Aged; Aged, 80 and over; Bacteremia; Bacterial Infections; Ceftazidime; Drug Resistance, Bacterial; Escherichia coli; Fever; Gram-Positive Bacteria; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Israel; Meropenem; Middle Aged; Odds Ratio; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Young Adult | 2012 |
Case-control study of drug monitoring of β-lactams in obese critically ill patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Case-Control Studies; Cefepime; Ceftazidime; Cephalosporins; Drug Monitoring; Enzyme Inhibitors; Female; Humans; Male; Meropenem; Middle Aged; Obesity; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Sepsis; Shock, Septic; Tazobactam; Thienamycins; Young Adult | 2013 |
Capnocytophaga canimorsus infection presenting with complete splenic infarction and thrombotic thrombocytopenic purpura: a case report.
Topics: Aged; Animals; Anti-Bacterial Agents; Bites and Stings; Capnocytophaga; Dogs; Gram-Negative Bacterial Infections; Humans; Imipenem; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Purpura, Thrombotic Thrombocytopenic; Splenic Infarction; Thienamycins | 2012 |
More potency assay results for generic non-USA lots of piperacillin/tazobactam and initial reports for generic meropenem compounds marketed in the USA.
Topics: Anti-Bacterial Agents; Drugs, Generic; Enterobacter cloacae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins; United States | 2013 |
Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Chromatography, Liquid; Critical Illness; Drainage; Exudates and Transudates; Female; Humans; Male; Meropenem; Middle Aged; Piperacillin; Plasma; Prospective Studies; Thienamycins; Urine | 2013 |
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Topics: Adult; Aged; Anti-Bacterial Agents; Creatinine; Critical Illness; Drug Delivery Systems; Female; Humans; Infusions, Intravenous; Kidney; Male; Meropenem; Metabolic Clearance Rate; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2013 |
β-Lactam antibiotics form distinct haptenic structures on albumin and activate drug-specific T-lymphocyte responses in multiallergic patients with cystic fibrosis.
Topics: Aztreonam; beta-Lactamase Inhibitors; beta-Lactams; Cystic Fibrosis; Drug Hypersensitivity; Haptens; Humans; Hypersensitivity; Meropenem; Molecular Structure; Piperacillin; Serum Albumin; T-Lymphocytes; Thienamycins | 2013 |
Antibiotics for the critically ill: more than just selecting appropriate initial therapy.
Topics: Critical Illness; Drug Delivery Systems; Female; Humans; Kidney; Male; Meropenem; Metabolic Clearance Rate; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2013 |
New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactam.
Topics: Aerosols; Ampicillin; Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Chemistry, Pharmaceutical; Equipment Design; Meropenem; Nebulizers and Vaporizers; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2013 |
Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Child; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Gentamicins; Hospitals, Pediatric; Humans; Italy; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Sulbactam; Thienamycins | 2013 |
Postoperative bacteriuria, pyuria and urinary tract infection in patients with an orthotopic sigmoid colon neobladder replacement.
Topics: Aged; Anti-Bacterial Agents; Bacteriuria; Cefepime; Cephalosporins; Colon, Sigmoid; Cystectomy; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Leukocyte Count; Levofloxacin; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Postoperative Complications; Prevalence; Pyuria; Staphylococcus aureus; Sulfamethoxazole; Tazobactam; Thienamycins; Trimethoprim; Urinary Diversion; Urinary Tract Infections | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Critical Illness; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intensive Care Units; Male; Meropenem; Metabolic Clearance Rate; Middle Aged; Piperacillin; Renal Replacement Therapy; Thienamycins; Vancomycin | 2014 |
Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis.
Topics: Aged; Anti-Bacterial Agents; Cohort Studies; Female; Humans; Infusions, Intravenous; Male; Meropenem; Middle Aged; Piperacillin; Prospective Studies; Thienamycins | 2014 |
In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Disease Models, Animal; Klebsiella Infections; Klebsiella pneumoniae; Lung; Male; Meropenem; Mice, Inbred BALB C; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Survival Analysis; Thienamycins | 2014 |
Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Drug Therapy, Combination; Febrile Neutropenia; Female; Humans; Infant; Male; Meropenem; Neoplasms; Neutrophils; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins; Young Adult | 2014 |
[Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
Topics: Acinetobacter baumannii; Acinetobacter Infections; Ampicillin; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefepime; Cephalosporins; Drug Resistance; Humans; In Vitro Techniques; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Pharmaceutical Preparations; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam; Thienamycins | 2014 |
Quantification of piperacillin, tazobactam, meropenem, ceftazidime, and linezolid in human plasma by liquid chromatography/tandem mass spectrometry.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Child; Chromatography, Liquid; Drug Monitoring; Humans; Limit of Detection; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam; Thienamycins | 2015 |
[Correlation between the biofilm-forming ability, biofilm-related genes and antimicrobial resistance of Acinetobacter baumannii].
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Biofilms; Cefepime; Cephalosporins; Drug Resistance, Bacterial; Meropenem; Piperacillin; Prospective Studies; Thienamycins | 2014 |
Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.
Topics: Analytic Sample Preparation Methods; Anti-Bacterial Agents; Automation; Blood Chemical Analysis; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Ciprofloxacin; Humans; Isotopes; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Thienamycins; Time Factors | 2015 |
β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Case-Control Studies; Extracorporeal Membrane Oxygenation; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Sepsis; Serum; Thienamycins; Treatment Outcome | 2015 |
Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital.
Topics: Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Inhibitory Concentration 50; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Republic of Korea; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tazobactam; Tertiary Care Centers; Thienamycins | 2015 |
[Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential].
Topics: Animals; Anti-Bacterial Agents; Bile; Cefoperazone; Drug Combinations; Meropenem; Metronidazole; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rabbits; Random Allocation; Sulbactam; Thienamycins | 2014 |
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Drug Combinations; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United States | 2015 |
Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA.
Topics: Allosteric Regulation; Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression; Humans; Linezolid; Meropenem; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Operon; Penicillanic Acid; Penicillin-Binding Proteins; Piperacillin; Staphylococcal Infections; Tazobactam; Thienamycins | 2015 |
Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DA
Topics: Aged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions, Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome | 2016 |
Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; Drug Combinations; Drug Synergism; Enterobacteriaceae; Escherichia coli Proteins; Gene Expression; Lactams; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Piperacillin; Plasmids; Protein Isoforms; Thienamycins | 2016 |
Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Aztreonam; Burns; Carbenicillin; Cefepime; Ceftazidime; Ceftriaxone; Cell Survival; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluorides; Gentamicins; Glass; Humans; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; NIH 3T3 Cells; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Silver; Thienamycins; Tobramycin; Wound Infection | 2016 |
Serum β-lactam concentrations in critically ill patients with cirrhosis: a matched case-control study.
Topics: Aged; Anti-Bacterial Agents; Belgium; Case-Control Studies; Chromatography, High Pressure Liquid; Critical Illness; Databases, Factual; Drug Monitoring; Female; Humans; Liver Cirrhosis; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Thienamycins | 2016 |
Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Nursing Homes; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; Retrospective Studies; Sputum; Taiwan; Thienamycins; Urine | 2016 |
What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Australia; Critical Illness; Female; Germany; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Obesity; Piperacillin; Plasma; Pseudomonas aeruginosa; Retrospective Studies; Spain; Thienamycins; Young Adult | 2016 |
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; Ceftazidime; Censuses; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Thienamycins; United States | 2016 |
A Microfluidic Channel Method for Rapid Drug-Susceptibility Testing of Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Escherichia coli; Lab-On-A-Chip Devices; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Thienamycins | 2016 |
Prospective Comparison of Acute Kidney Injury During Treatment With the Combination of Piperacillin-Tazobactam and Vancomycin Versus the Combination of Cefepime or Meropenem and Vancomycin.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Vancomycin | 2017 |
In Vitro and In Vivo Activities of OP0595, a New Diazabicyclooctane, against CTX-M-15-Positive Escherichia coli and KPC-Positive Klebsiella pneumoniae.
Topics: Azabicyclo Compounds; beta-Lactamases; Cefepime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin; Thienamycins | 2016 |
Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: a retrospective observational study.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Ceftazidime; Drug Resistance, Microbial; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2016 |
Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Chemical and Drug Induced Liver Injury; Cholestasis; Critical Illness; Drug Monitoring; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Renal Replacement Therapy; Retrospective Studies; Seizures; Thienamycins; Thrombocytopenia | 2016 |
In Vivo and In Vitro Efficacy of Minocycline-Based Combination Therapy for Minocycline-Resistant Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Biofilms; Cefepime; Cephalosporins; Colistin; Drug Resistance, Multiple, Bacterial; Gentamicins; Imipenem; Meropenem; Mice; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Taiwan; Thienamycins | 2016 |
Dynamics of Mutations during Development of Resistance by Pseudomonas aeruginosa against Five Antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Ceftazidime; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Microbial; Meropenem; Microbial Sensitivity Tests; Mutation; Piperacillin; Pseudomonas aeruginosa; Thienamycins; Tobramycin | 2016 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
[The activity of moxalactam against Enterobacteriaceae and anaerobia in vitro].
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Cefoperazone; Enterobacteriaceae; Escherichia coli; Imipenem; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Moxalactam; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus; Thienamycins | 2016 |
[Study on drug sensitivity against Comamonas testosteroni by Kirby-Bauer disk diffusion method].
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Comamonas testosteroni; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Thienamycins | 2016 |
Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.
Topics: Aged; Anti-Bacterial Agents; Female; Glomerular Filtration Rate; Humans; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins | 2016 |
Effective Antibiotic Conservation by Emergency Antimicrobial Stewardship During a Drug Shortage.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Antimicrobial Stewardship; Hospital Mortality; Humans; Length of Stay; Linear Models; Meropenem; Missouri; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2017 |
Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamase Inhibitors; Ceftazidime; Drug Synergism; Kinetics; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Tandem Mass Spectrometry; Thienamycins | 2017 |
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Stenotrophomonas maltophilia; Tazobactam; Thienamycins | 2017 |
Antimicrobial resistance in the Bacteroides fragilis group in faecal microbiota from healthy Danish children.
Topics: Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; Child; Clindamycin; Denmark; Drug Resistance, Bacterial; Feces; Humans; Meropenem; Metronidazole; Microbial Sensitivity Tests; Microbiota; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surveys and Questionnaires; Thienamycins | 2017 |
Therapeutic drug monitoring of beta-lactam antibiotics - Influence of sample stability on the analysis of piperacillin, meropenem, ceftazidime and flucloxacillin by HPLC-UV.
Topics: Anti-Bacterial Agents; Ceftazidime; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Floxacillin; Meropenem; Piperacillin; Thienamycins | 2017 |
Clinical Outcome and Antimicrobial Therapeutic Drug Monitoring for the Treatment of Infections in Acute Burn Patients.
Topics: Acinetobacter Infections; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Burns; Child; Child, Preschool; Cross Infection; Drug Monitoring; Female; Humans; Imipenem; Infant; Intensive Care Units; Male; Meropenem; Middle Aged; Piperacillin; Pneumonia; Prognosis; Tertiary Care Centers; Thienamycins; Urinary Tract Infections; Vancomycin; Young Adult | 2017 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Dosing antibiotics in neonates: review of the pharmacokinetic data.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Birth Weight; Body Size; Cephalosporins; Child; Clindamycin; Glycopeptides; Humans; Infant; Infant, Newborn; Medication Reconciliation; Meropenem; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2017 |
Influence of β-Lactam Infusion Strategy on Acute Kidney Injury.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Cefepime; Cephalosporins; Drug Therapy, Combination; Female; Humans; Kidney; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Automated direct screening for resistance of Gram-negative blood cultures using the BD Kiestra WorkCell.
Topics: Ampicillin; Anti-Bacterial Agents; Bacteremia; Blood Culture; Ceftriaxone; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Gentamicins; Gram-Negative Bacteria; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2018 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Reply to MacFadden et al.
Topics: Bacteremia; Cefepime; Gram-Negative Bacteria; Humans; Meropenem; Piperacillin; Sepsis; Tazobactam | 2018 |
Development and validation of an LC tandem MS assay for the quantification of β-lactam antibiotics in the sputum of cystic fibrosis patients.
Topics: Anti-Bacterial Agents; Aztreonam; Ceftazidime; Chromatography, High Pressure Liquid; Cystic Fibrosis; Humans; Meropenem; Piperacillin; Sputum; Tandem Mass Spectrometry; Thienamycins | 2018 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Clostridium Infections; Cohort Studies; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Floxacillin; Humans; Incidence; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Neurotoxicity Syndromes; Piperacillin; Retrospective Studies; Thienamycins | 2017 |
Proficiency Testing for Meropenem and Piperacillin Therapeutic Drug Monitoring: Preliminary Results From the Belgian Society on Infectiology and Clinical Microbiology Pharmacokinetic-Pharmacodynamic Working Group.
Topics: Anti-Bacterial Agents; Drug Monitoring; Humans; Laboratory Proficiency Testing; Meropenem; Piperacillin; Thienamycins | 2018 |
Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Carbapenem-Resistant Enterobacteriaceae; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Retrospective Studies; Tertiary Care Centers; Thienamycins; Treatment Outcome | 2018 |
Considerable variation of trough β-lactam concentrations in older adults hospitalized with infection-a prospective observational study.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Bacterial Infections; beta-Lactams; Cefotaxime; Drug Monitoring; Female; Humans; Length of Stay; Male; Meropenem; Patient Readmission; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sepsis; Sweden; Thienamycins | 2018 |
Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2018 |
Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?
Topics: Acute Kidney Injury; Adult; Aged; Creatinine; Drug Therapy, Combination; Female; Humans; Kidney; Logistic Models; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Staphylococcal Infections; Thienamycins; Vancomycin | 2018 |
Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program,
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Colistin; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; United States | 2018 |
[Analysis of the distribution characteristics and drug resistance of non-fermenting bacterial infection in intensive care unit from 2009 to 2015]
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cefoperazone; Cephalosporins; Cross Infection; Drug Resistance; Drug Resistance, Bacterial; Gram-Negative Bacteria; Humans; Imipenem; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Retrospective Studies; Thienamycins | 2016 |
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation.
Topics: Anti-Bacterial Agents; Cefepime; Chromatography, Liquid; Drug Stability; Humans; Meropenem; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Temperature | 2018 |
Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Chromatography, Liquid; Humans; Meropenem; Piperacillin; Sensitivity and Specificity; Tandem Mass Spectrometry; Tazobactam | 2018 |
Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
Topics: Anti-Bacterial Agents; Cefepime; Critical Illness; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tazobactam | 2018 |
Beta-lactam carryover in arterial and central venous catheters is negligible.
Topics: Animals; Catheters, Indwelling; Cattle; Cefepime; Central Venous Catheters; Chromatography, High Pressure Liquid; Meropenem; Piperacillin; Vancomycin | 2018 |
Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Critical Illness; Drug Monitoring; Female; Humans; Logistic Models; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Prospective Studies; Treatment Outcome | 2018 |
The Reaction Mechanism of Metallo-β-Lactamases Is Tuned by the Conformation of an Active-Site Mobile Loop.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Catalytic Domain; Cefepime; Cefotaxime; Ceftazidime; Cloning, Molecular; Crystallography, X-Ray; Escherichia coli; Gene Expression; Genetic Vectors; Imipenem; Kinetics; Meropenem; Models, Molecular; Piperacillin; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Engineering; Protein Interaction Domains and Motifs; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Substrate Specificity; Zinc | 2019 |
The addition of avibactam renders piperacillin an effective treatment for
Topics: Animals; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Disease Models, Animal; Drug Combinations; Drug Synergism; Meropenem; Microbial Sensitivity Tests; Moths; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Piperacillin | 2018 |
Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem.
Topics: Acute Kidney Injury; Aged; Cefepime; Critical Illness; Female; Humans; Incidence; Male; Meropenem; Middle Aged; Multivariate Analysis; Piperacillin; Retrospective Studies; Tazobactam; Vancomycin | 2019 |
LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples.
Topics: Anti-Bacterial Agents; Chromatography, Liquid; Drug Monitoring; Humans; Limit of Detection; Linezolid; Meropenem; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry; Teicoplanin | 2019 |
Adequacy of empiric gram-negative coverage for septic patients at an academic medical center.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Female; Gram-Negative Bacteria; Humans; Levofloxacin; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Sepsis; Shock, Septic; Virginia; Young Adult | 2019 |
Stability Studies of Antipyocyanic Beta-Lactam Antibiotics Used in Continuous Infusion.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Imipenem; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam | 2019 |
UPLC/MS/MS assay for the simultaneous determination of seven antibiotics in human serum-Application to pediatric studies.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Blood Chemical Analysis; Calibration; Cefotaxime; Child; Child, Preschool; Chromatography, High Pressure Liquid; Ciprofloxacin; Escherichia coli Infections; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Limit of Detection; Male; Meropenem; Metronidazole; Pediatrics; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry | 2019 |
Antimicrobial Disposition During Pediatric Continuous Renal Replacement Therapy Using an Ex Vivo Model.
Topics: Amphotericin B; Anti-Infective Agents; Caspofungin; Continuous Renal Replacement Therapy; Dose-Response Relationship, Drug; Humans; Meropenem; Metabolic Clearance Rate; Models, Biological; Pediatrics; Piperacillin; Voriconazole | 2019 |
Preanalytical Stability of Piperacillin, Tazobactam, Meropenem, and Ceftazidime in Plasma and Whole Blood Using Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Anti-Bacterial Agents; Ceftazidime; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Meropenem; Piperacillin; Plasma; Tandem Mass Spectrometry; Tazobactam | 2019 |
Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Drug Monitoring; Female; Humans; Male; Meropenem; Middle Aged; Piperacillin; Protein Binding; Young Adult | 2020 |
Comparative LC-MS/MS and HPLC-UV Analyses of Meropenem and Piperacillin in Critically Ill Patients.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Critical Care; Critical Illness; Drug Monitoring; Humans; Meropenem; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry; Ultraviolet Rays | 2019 |
Topics: Achromobacter; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Burkholderia; Cystic Fibrosis; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Stenotrophomonas; Stenotrophomonas maltophilia; Tazobactam | 2019 |
In vitro activity of meropenem/piperacillin/tazobactam triple combination therapy against clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus pseudintermedius and vancomycin-resistant Enterococcus spp.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Genome, Bacterial; Genomics; Humans; Meropenem; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Staphylococcal Infections; Staphylococcus; Staphylococcus epidermidis; Tazobactam; Vancomycin-Resistant Enterococci; Whole Genome Sequencing | 2020 |
Prevalence and antimicrobial susceptibility of enterotoxigenic extra-intestinal Bacteroides fragilis among 13-year collection of isolates in Kuwait.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Toxins; Bacteroides fragilis; Bacteroides Infections; Cefoxitin; Clindamycin; Drug Resistance, Bacterial; Feces; Female; Humans; Imipenem; Kuwait; Male; Meropenem; Metronidazole; Microbial Sensitivity Tests; Piperacillin; Prevalence; Prospective Studies; Respiratory Tract Infections; Sepsis; Tigecycline; Wound Infection | 2020 |
The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study.
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Meropenem; Piperacillin; Prospective Studies; Renal Replacement Therapy | 2021 |
What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Computer Simulation; Humans; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Shock, Septic | 2020 |
The ONTAI study - a survey on antimicrobial dosing and the practice of therapeutic drug monitoring in German intensive care units.
Topics: Anti-Bacterial Agents; Critical Care; Critical Illness; Cross-Sectional Studies; Drug Monitoring; Germany; Humans; Intensive Care Units; Meropenem; Microbial Sensitivity Tests; Physicians; Piperacillin; Surveys and Questionnaires; Treatment Outcome; Vancomycin | 2020 |
Demonstrating Feasibility of an Opportunistic Sampling Approach for Pharmacokinetic Studies of β-Lactam Antibiotics in Critically Ill Children.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactams; Cefepime; Child; Child, Preschool; Comorbidity; Critical Illness; Feasibility Studies; Female; Humans; Intensive Care Units, Pediatric; Male; Meropenem; Piperacillin; Prospective Studies | 2021 |
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".
Topics: Anti-Bacterial Agents; Cefepime; Humans; Meropenem; Piperacillin; Protein Binding; Tazobactam | 2020 |
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples".
Topics: Anti-Bacterial Agents; Cefepime; Humans; Meropenem; Piperacillin; Protein Binding; Tazobactam | 2020 |
Risk of Acute Kidney Injury and Clostridioides difficile Infection With Piperacillin/Tazobactam, Cefepime, and Meropenem With or Without Vancomycin.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Clostridioides; Drug Therapy, Combination; Humans; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2021 |
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
A new HPLC-MS/MS analytical method for quantification of tazobactam, piperacillin, and meropenem in human plasma.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Limit of Detection; Meropenem; Piperacillin; Plasma; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2021 |
A worldwide pharmacovigilance database analysis to assess the risk of acute kidney injury in patients receiving teicoplanin in association with piperacillin, cefepime or meropenem.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Humans; Meropenem; Pharmacovigilance; Piperacillin; Teicoplanin | 2021 |
Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum.
Topics: Cefepime; Chromatography, Liquid; Humans; Meropenem; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2021 |
Meropenem and piperacillin-tazobactam levels for critical care patients during empiric therapy.
Topics: Anti-Bacterial Agents; Critical Care; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2021 |
Meropenem Use in Pediatric Oncology - Audit on Indication, Appropriateness and Consumption Comparing Patient Derived and Pharmacy Dispensing Data.
Topics: Anti-Bacterial Agents; Child; Humans; Meropenem; Neoplasms; Penicillanic Acid; Pharmacy; Piperacillin; Retrospective Studies | 2021 |
Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Cefepime; Drug Therapy, Combination; Humans; Incidence; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2022 |
Development and validation of a liquid chromatography high-resolution mass spectrometry orbitrap method for the sensitive quantification of amoxicillin, piperacillin, tazobactam and meropenem in human faeces.
Topics: Amoxicillin; Anti-Bacterial Agents; Chromatography, Liquid; Feces; Humans; Mass Spectrometry; Meropenem; Piperacillin; Research Design; Tazobactam | 2021 |
Pilot study of oral fluid and plasma meropenem and piperacillin concentrations in the intensive care unit.
Topics: Adult; Aged; Anti-Bacterial Agents; Critical Illness; Humans; Intensive Care Units; Meropenem; Middle Aged; Pilot Projects; Piperacillin; Young Adult | 2021 |
Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Critical Illness; Humans; Meropenem; Microbial Sensitivity Tests; Monte Carlo Method; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study.
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Meropenem; Piperacillin; Renal Dialysis | 2022 |
Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Cefepime; Cohort Studies; Critical Illness; Drug Therapy, Combination; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Retrospective Studies; Vancomycin | 2022 |
β-lactam dosing at the early phase of sepsis: Performance of a pragmatic protocol for target concentration achievement in a prospective cohort study.
Topics: Anti-Bacterial Agents; beta-Lactams; Critical Illness; Humans; Meropenem; Piperacillin; Prospective Studies; Sepsis | 2022 |
Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Critical Illness; Drug Monitoring; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Singapore | 2022 |
Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Ceftazidime; Cephalosporins; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Monobactams; Piperacillin; Pseudomonas aeruginosa; Tazobactam | 2022 |
Interactions Between Meropenem and Renal Drug Transporters.
Topics: Animals; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Interactions; Humans; Kidney; Membrane Transport Proteins; Meropenem; Neoplasm Proteins; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Piperacillin; Rats | 2022 |
Letter to the editor: "Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study".
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Infusions, Intravenous; Meropenem; Piperacillin; Renal Dialysis; Thienamycins | 2022 |
Authors response: "Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational study".
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Infusions, Intravenous; Meropenem; Piperacillin; Renal Dialysis; Thienamycins | 2022 |
[Personalized intensive care medicine : Implementation of therapeutic drug monitoring to assess antibiotic levels in intensive care patients].
Topics: Anti-Bacterial Agents; Ceftazidime; Ceftriaxone; Critical Care; Drug Monitoring; Humans; Meropenem; Piperacillin; Retrospective Studies; Tigecycline | 2023 |
Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Deoxyribonucleases; Drug Resistance, Bacterial; Genotype; Gentamicins; Humans; Imipenem; Iran; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Pancreatic Elastase; Phospholipases; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Escherichia coli; Escherichia coli Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2022 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Drug Therapy, Combination; Humans; Incidence; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2022 |
Clinical Characteristics and Drug Resistance Analysis of 90 Cases of Children with Salmonella Enteritis.
Topics: Anti-Bacterial Agents; Case-Control Studies; Cephalosporins; Child; Drug Resistance; Enteritis; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Retrospective Studies | 2022 |
An Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Determination of 4 β-Lactam Antibiotics, Tazobactam, and Linezolid in Human Plasma Samples.
Topics: Anti-Bacterial Agents; Cefepime; Cefotaxime; Chromatography, High Pressure Liquid; Critical Illness; Drug Monitoring; Humans; Linezolid; Meropenem; Monobactams; Piperacillin; Reproducibility of Results; Tandem Mass Spectrometry; Tazobactam | 2022 |
Meropenem-loaded Cement Is Effective in Preventing Gram-negative Osteomyelitis in an Animal Model.
Topics: Animals; Anti-Bacterial Agents; Aztreonam; Bone Cements; Ceftazidime; Ciprofloxacin; Escherichia coli; Male; Meropenem; Microbial Sensitivity Tests; Models, Animal; Osteomyelitis; Piperacillin; Rats; Tobramycin | 2023 |
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Topics: Ampicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Klebsiella pneumoniae; Levofloxacin; Meropenem; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Tazobactam; Tigecycline | 2022 |
PAUSATE Study: Prevalence and appropriateness of the use of antimicrobials in Spanish hospitals.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Clavulanic Acid; Cross-Sectional Studies; Hospitals; Humans; Meropenem; Piperacillin; Prevalence; Tazobactam | 2022 |
Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Topics: Anti-Bacterial Agents; Body Weight; Cefepime; Ceftazidime; Critical Illness; Humans; Lactams; Meropenem; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2022 |
Piperacillin/tazobactam and risk of acute kidney injury in adults hospitalized with infection without vancomycin: a multi-centre real-world data analysis.
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Ceftazidime; Data Analysis; Drug Therapy, Combination; Female; Humans; Meropenem; Middle Aged; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2023 |
Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
Topics: Anti-Bacterial Agents; Bayes Theorem; beta-Lactams; Cefotaxime; Child; Critical Illness; Humans; Infusions, Intravenous; Meropenem; Piperacillin; Prospective Studies | 2023 |
Accuracy of a precision dosing software program for predicting antibiotic concentrations in critically ill patients.
Topics: Anti-Bacterial Agents; Critical Illness; Drug Monitoring; Humans; Meropenem; Piperacillin; Sepsis; Software; Vancomycin | 2023 |
Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates.
Topics: Amikacin; Amoxicillin; Anti-Bacterial Agents; Cefepime; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Genotype; Gentamicins; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin; Retrospective Studies; Tazobactam; Tobramycin; Whole Genome Sequencing | 2023 |
Impact of an antibiotic stewardship program on antibiotic utilization, bacterial susceptibilities, and cost of antibiotics.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antimicrobial Stewardship; Hospitals, University; Humans; Meropenem; Piperacillin; Retrospective Studies; Tigecycline | 2023 |
A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cefepime; Critical Illness; Drug Therapy, Combination; Humans; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Vancomycin | 2023 |
Geographic patterns of antimicrobial susceptibilities for Bacteroides spp. worldwide: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2007-2020.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteroides fragilis; Bacteroides Infections; Cefoxitin; Clindamycin; Humans; Leadership; Meropenem; Microbial Sensitivity Tests; Piperacillin; Tazobactam; Tigecycline | 2023 |
Stability of 10 Beta-Lactam Antibiotics in Human Plasma at Different Storage Conditions.
Topics: Amoxicillin; Anti-Bacterial Agents; Cefotaxime; Ceftazidime; Ceftriaxone; Cefuroxime; Floxacillin; Humans; Imipenem; Meropenem; Monobactams; Piperacillin; Tandem Mass Spectrometry | 2023 |
Efficacy and safety of piperacillin-tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing
Topics: Adult; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Urinary Tract Infections | 2023 |
A case of Robinsoniella peoriensis bacteremia during using piperacillin-tazobactam.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Female; Fever; Humans; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Vancomycin | 2023 |
Topics: Achromobacter; Anti-Bacterial Agents; Cystic Fibrosis; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Tazobactam | 2023 |
International survey of antibiotic dosing and monitoring in adult intensive care units.
Topics: Adult; Aminoglycosides; Anti-Bacterial Agents; Critical Illness; Cross-Sectional Studies; Humans; Intensive Care Units; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surveys and Questionnaires; Vancomycin | 2023 |
In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.
Topics: Amikacin; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thailand | 2023 |
Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program.
Topics: Anti-Bacterial Agents; Bayes Theorem; Child; Clindamycin; Critical Illness; Fluconazole; Humans; Linezolid; Meropenem; Metronidazole; Neoplasms; Piperacillin; Vancomycin | 2023 |